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ABSTRACT 
LEAH L. ZULLIG: Equity in an Equal Access System? – Quality & Timeliness of 
Cancer Care in the Veterans Affairs Healthcare System 
(Under the direction of William R. Carpenter, PhD) 
 
The objective of this dissertation was to examine the association between 
patients’ race and receipt of National Comprehensive Cancer Network guideline-
adherent and timely colorectal cancer (CRC) and non-small cell lung cancer 
(NSCLC) care in the Veterans Affairs (VA) healthcare system. Data were from the 
External Peer Review Program (EPRP) Special Study on CRC and NSCLC, 
originally purposed for performance monitoring, examined in an observational, 
retrospective study design. The sample consisted of African American (AA) and 
Caucasian patients diagnosed with CRC between 2003 and 2006 or NSCLC 
between 2006 and 2007 at VA hospitals nationwide. Statistical analysis approaches 
included multivariate logistic regression and survival analysis methods.  
Our first analysis used multivariable logistic regression to examine 
associations between race and receipt of guideline-concordant care (computed 
tomography scan, preoperative carcinoembryonic antigen, clear surgical margins, 
medical oncology referral for Stages II-III; fluorouracil-based adjuvant chemotherapy 
for Stage III; surveillance colonoscopy for Stages I-III). There were no significant 
racial differences in receipt of guideline-concordant CRC care. Our second analysis 
examined associations between race and CRC care timeliness. There were no racial 
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differences in time to chemotherapy initiation (HR 0.82, p=0.61) or surgery to death 
(HR 0.94, p=0.0.49). Caucasian race was protective for shorter time to first 
surveillance colonoscopy (HR 0.63, p=0.02). On average, the difference in time to 
colonoscopy was sixteen days. Our third analysis examined associations between 
race and NSCLC care timeliness. There were no racial differences in time to 
initiation of treatment (72 days for AA versus 65 days for Caucasian patients, HR 
1.03, p=0.80) or palliative care or hospice referral (129 versus 116 days, HR 1.10, 
p=0.34). However, the adjusted model found longer survival for African American 
compared to Caucasian patients (133 versus 117 days, HR 1.31, p=0.00).  
In these data there were minimal statistically significant racial differences. We 
identified no clinically meaningful racial differences in cancer care quality, timeliness, 
or patient outcomes. This suggests that VA may be a leader in providing equitable 
cancer care. Future studies could examine causal pathways for the VA’s equal, 
quality care and ways to translate the VA’s success into other hospital systems.  
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 CHAPTER 1: INTRODUCTION
In the United States, lung and colorectal cancer (CRC) are the second and 
third most commonly diagnosed cancers and the first and third leading causes of 
cancer-related death respectively (Jemal, Siegel, Xu, & Ward, 2010; Siegel, 
Naishadham, & Jemal, 2012). For both CRC and lung cancer, there is evidence that 
mortality rates at every stage of disease are higher among African Americans than 
Caucasian patients (Jemal et al., 2010; Shavers & Brown, 2002). Despite the 
existence of numerous evidence-based clinical practice guidelines for the treatment 
of CRC and lung cancer, standards for timeliness of care remain a matter of expert 
consensus, and there is wide variation in the quality and timeliness of care delivered 
to patients. Nationally, there is increasing pressure to improve the quality of cancer 
care delivered in the United States. The Institute of Medicine (IOM) report titled 
“Crossing the Quality Chasm” outlined six aims for high-quality healthcare—
effective, safe, timely, efficient, equitable, and patient-centered (America & Medicine, 
2001). A national panel of experts considered these aims and recommended that 
standardizing patient care and adhering to clinical practice guidelines are essential 
for improving cancer care quality (Aiello Bowles et al., 2008). 
Research suggests that much of the variation in quality of cancer care is 
associated with patients’ race and socioeconomic status (Shavers & Brown, 2002). 
An abundance of literature indicates that racial disparities in cancer care persist in 
private U.S. healthcare systems (Baldwin et al., 2005; Demissie et al., 2004; George 
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& Margolis, 2010; Govindarajan, Shah, Erkman, & Hutchins, 2003; Polite, Dignam, & 
Olopade, 2005; Schrag, Cramer, Bach, & Begg, 2001; Schwartz, Crossley-May, 
Vigneau, Brown, & Banerjee, 2003; Shih, Elting, & Halpern, 2009). Although the 
Veterans Affairs (VA) healthcare system is reputed as an equal-access system, 
there is a paucity of literature addressing differences in the quality of treatment for 
patients of diverse races with CRC or lung cancer. More than a decade ago, 
research results suggested that for patients receiving cancer care in the VA there 
was no association between race and whether patients received basic treatment 
elements like surgery, chemotherapy, and radiation therapy (Dominitz, Samsa, 
Landsman, & Provenzale, 1998; Page & Kuntz, 1980). However, the same study 
also reported that all-cause mortality was higher among African American veterans 
with CRC compared to Caucasian veterans (Dominitz et al., 1998). As time has 
progressed, treatment options and patterns of care have evolved and the 
association between quality of care and race may have changed. For example, in 
non-VA healthcare settings people of minority race are less likely to receive cutting-
edge biologic drug agents like bevacizumab for the treatment of advanced CRC 
(Shih et al., 2009). More recent studies have found no racial difference in stage of 
disease at diagnosis, time to referral, or five-year survival among CRC patients. 
However, these studies have focused on a specific VA hospital rather than 
assessing a national cohort of patients, which limits generalizability to all VA 
healthcare settings (Robinson et al., 2010; Sabounchi, Keihanian, & Anand, 2012). 
Consequently, further examination is required to determine whether racial equity 
exists in the VA system on a national scale.  
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Globally, recent evidence suggests the overall quality of cancer care in the 
VA is equal to or exceeds the care offered in the private sector (Jackson, Melton, et 
al., 2010; Keating et al., 2011; Trivedi et al., 2011). A recent exploratory analysis 
indicated that African American race may be associated with lower odds of receiving 
surveillance colonoscopy (Zullig, Provenzale, McNeil, Abbott, & Jackson, 2011). 
However, little is known about the juxtaposition of race and quality of cancer 
treatment in the modern VA healthcare system. Thus, this dissertation will examine 
the relationship between patient characteristics (specifically race) and receipt of 
high-quality, timely cancer treatment and surveillance services among a VA patient 
population. The VA healthcare system, the nation’s largest provider of cancer care, 
serves a distinctive population and has unique data collection abilities. Specifically, 
this dissertation will focus on the relationship between veterans’ race and receipt of 
guideline-adherent and timely CRC and lung cancer care. Understanding this 
relationship is an essential step toward developing effective interventions to reduce 
racial disparities in quality and timeliness of cancer care, resulting in equity for all VA 
patients.  
The central hypothesis of this dissertation is that African American patients 
will be less likely to receive guideline-adherent and timely CRC and lung cancer care 
and will have poorer health outcomes, than Caucasian patients in the VA healthcare 
system. The specific aims are to: 
 Aim 1: Examine patient-level factors associated with receipt of 
National Comprehensive Cancer Network (NCCN) guideline-
adherent CRC care (Chapter 4). 
 Aim 2: Examine patient-level factors associated with (a) receipt of 
timely CRC care and (b) subsequent health outcomes (Chapter 5). 
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 Aim 3: Examine patient-level factors associated with (a) receipt of 
timely lung cancer care and (b) subsequent health outcomes 
(Chapter 6). 
 
The primary data source for the dissertation was the External Peer Review 
Program (EPRP) data (Jackson, Melton, et al., 2010; Kussman, 2008). EPRP data 
have informed health services research assessing care for VA patients with 
diabetes, implications of a pneumonia screening program, and the diagnosis and 
treatment of CRC, among other health issues (Jackson, Melton, et al., 2010; Reed, 
Baumann, Petzel, & Weeks, 1996; Sawin, Walder, Bross, & Pogach, 2004). This 
dissertation followed a similar data linkage strategy. 
The EPRP CRC data (Aims 1 and 2) were collected between July and August 
2007. Retrospective chart abstraction was completed for approximately 2,492 
patients with incident Stage I to III CRC. To be included in the EPRP data collection, 
patients had to: be diagnosed with CRC between October 1, 2003, and March 31, 
2006; have undergone definitive CRC surgery; and been treated at one or more of 
128 VA Medical Centers (VAMCs) (Goulet et al., 2007; Jackson, Melton, et al., 
2010). Similarly, for the EPRP lung cancer data set (Aim 3), retrospective chart 
abstraction was completed for approximately 1,161 patients diagnosed with incident, 
non-metastatic, non-small cell lung cancer (NSCLC) diagnosed between October 1, 
2006, and December 31, 2007, who underwent definitive lung cancer surgery and 
were treated in a VAMC. Retrospective data collection for the NSCLC cohort 
occurred between February 3, 2010 and August 11, 2010.  
The analytic approach for Aim 1 included multivariable logistic regression 
models controlling for demographic characteristics, comorbid conditions, and health 
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characteristics. The analytic approach for Aim 2 included Cox proportional hazard 
models to examine racial differences in timeliness of care and subsequent health 
outcomes, controlling for demographic characteristics, comorbid conditions, and 
health characteristics. The Cox proportional hazard model enabled the assessment 
of two factors simultaneously: (1) whether or not an event occurred, and (2) if the 
event occurred, the time to the event (Kleinbaum, 1996). Furthermore, Cox 
proportional hazard models permitted censoring which is important in the current 
context. Censoring occurs when only part of the data is known. For example, the 
data may be right-censored because of an event occurring (i.e., the patient died) or 
because of when the data were collected (i.e., the patient was still alive at the time of 
data collection). Another advantage of the Cox proportional hazard model is that it 
allows for proportional effects to vary over time. For example, the effect of receiving 
a surveillance colonoscopy at twelve months post–surgical resection may have a 
different effect on likelihood of death compared to having a surveillance colonoscopy 
at eighteen months. As a result the Cox proportional hazard regression models can 
estimate the relative risks of a delay in treatment for patients of different races (i.e., 
Caucasian and African American), controlling for patient characteristics, regional 
characteristics, and health status. Because institutions or service networks may 
have different policies and organizational cultures affecting delivery of high-quality 
cancer care, use of clustered standard errors by geographic region was examined. 
The small numbers of patients at individual medical centers prevented clustering at 
the facility level. 
Aim 3 used the NSCLC EPRP data set. The study sample consisted of male 
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patients who were diagnosed with incident, non-metastatic, NSCLC diagnosed 
between October 1, 2006, and December 31, 2007, who underwent definitive lung 
cancer surgery and were treated in at least one or more of the 128 VA medical 
centers nationwide. Mirroring the previous aim, Aim 3 also utilized a Cox 
proportional hazard model. Key explanatory variables and covariates were 
consistent across all three aims.  
This research advances previous VA racial disparities literature in several 
regards. First, prior work in CRC care relied exclusively on VA administrative data 
(Dominitz et al., 1998). This dissertation will supplement administrative data with 
information that was manually collected from the electronic health record, thus 
providing insights into the patient care process. Second, prior research has focused 
on whether or not patients of minority and majority race received a specific 
component of cancer care such as chemotherapy or surgery. This dissertation 
enhances the current knowledge because examined not only whether cancer care 
was received but also whether that care was concordant with current clinical practice 
guidelines. Moreover, this dissertation examined not only processes of care but 
extends prior knowledge by examining health outcomes. By examining processes of 
care and health outcomes in tandem, it was possible to assess whether equality in 
health services creates equity in health outcomes. 
It was anticipated that these aims would yield the following expected 
outcomes. First, this dissertation would identify modifiable characteristics that place 
patients at risk of not receiving guideline-adherent cancer care along the cancer care 
continuum (Zapka, Taplin, Solberg, & Manos, 2003). Identifying patients at risk for 
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poor quality of care is relevant to policy makers who seek to identify a target 
population most likely to benefit from future quality improvement interventions and, 
ultimately, save scarce resources. Second, this dissertation would generate new 
evidence about the timeliness of CRC (Aim 2) and NSCLC (Aim 3) care and 
subsequent health outcomes. This allowed us to examine whether timeliness of care 
has a meaningful effect on health outcomes, as well as identify a target population 
most likely to benefit from future timeliness of care interventions. Targeting 
vulnerable populations for interventions will ultimately conserve resources as 
interventions focus on patients and elements of the cancer care continuum with the 
greatest need.  
Furthermore, the dissertation makes a timely contribution during a time of 
U.S. healthcare reform. As a result of the Patient Protection and Affordable Care Act 
of 2010, it is likely that some semblance of Accountable Care Organizations (ACOs) 
will be put in place ("Medicare program; Medicare Shared Savings Program: 
Accountable Care Organizations. Final rule," 2011). ACOs generally include a 
patient-centered medical home embedded in an integrated and organized health 
delivery system, including services like home health agencies and specialty care 
(Shortell, Casalino, & Fisher, 2010). Central to the concept of an ACO is timely 
performance measurement and feedback (Fisher & Shortell, 2010; Shortell et al., 
2010). Feedback should be focused at an organizational level because poor 
performance is viewed as a consequent system failure rather than being the 
responsibility of any one clinician or administrator (Fisher & Shortell, 2010). 
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At its core, the VA is an ACO. Compared to other U.S. healthcare systems, 
the VA is unique because it is an integrated health care system that assumes 
responsibility for the distinctive veteran population. The VA is also unique because 
of its longstanding history and dedication to quality measurement and performance 
improvement. Because the VA serves as a model of an ACO, the methods and 
results of the dissertation will be applicable to future integrated health care systems 
or ACOs nationwide. Additionally, with the large number of veterans returning from 
current conflicts the VA will have to learn to efficiently manage its resources to 
continue as an exemplar ACO. This adds to the VA’s national relevance. The 
American healthcare system will undergo similar struggles as it increases access to 
approximately 30 million American citizens (An act entitled The Patient Protection 
and Affordable Care Act, 2010). 
Sections of the dissertation are organized as follows: Chapter 2 discusses 
current literature regarding CRC and lung cancer disparities, quality of cancer care, 
the VA healthcare system, the quality of care in the VA, and the multiplicity of factors 
that may have effect on the quality of care received. It concludes by exploring the 
limitations of existing studies and further provides support from existing literature 
and justification for the dissertation research. Chapter 3 provides an overview of the 
methods used throughout the dissertation. It includes a discussion of study design 
and rationale, data sources, hypotheses, and analytical approaches. Chapters 4-6 
are manuscripts corresponding to Aims 1-3, respectively, and are intended for 
submission for peer-reviewed publication. Chapter 7 reviews the strengths and 
limitations of this dissertation, its policy relevance, and future research plans. 
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References are provided in a comprehensive bibliography at the conclusion of the 
dissertation. 
 
 CHAPTER 2: LITERATURE REVIEW 
Overview 
Racial disparities in cancer care are a complex and multifaceted issue. 
Evidence regarding the existence and severity of racial disparities is often 
inconsistent, making it difficult to disentangle the overall impact and sources of the 
problem. Racial disparities have been documented in stages of diagnosis (Berry et 
al., 2009; Bradley, Given, & Roberts, 2001; Polite et al., 2005), diagnostic evaluation 
procedures (Laiyemo et al., 2010), receipt of adjuvant chemotherapy for CRC 
patients (Baldwin et al., 2005; Govindarajan et al., 2003; Schrag et al., 2001), receipt 
of radiation therapy for rectal cancer patients (Ayanian et al., 2003), timeliness of 
care and receipt of surgery for early stage lung cancer patients (George & Margolis, 
2010; Suga et al., 2010), participation in clinical trials (Murthy, Krumholz, & Gross, 
2004), and survival (D. D. Alexander et al., 2007; Berry et al., 2009; Bradley et al., 
2001; Pulte, Redaniel, Brenner, & Jeffreys, 2012). The impact of race on receipt of 
cancer care may be confounded by factors including socioeconomic status, 
geography, and organizational characteristics of healthcare services (Akerley, 
Moritz, Ryan, Henderson, & Zacharski, 1993; Ayanian et al., 2003; Berry et al., 
2009; Du, Lin, Johnson, & Altekruse, 2011; Pagano et al., 2010; Schwartz et al., 
2003; Shih et al., 2009). Despite these well-documented examples of racial 
disparities, numerous studies find no or slight racial differences in cancer care 
(Dominitz et al., 1998; Robinson et al., 2010; Sabounchi et al., 2012). Although 
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studies conducted in different settings and populations often yield incongruent 
results, one thing is clear; racial disparities in cancer care are a serious concern 
affecting the consistency and quality of cancer care nationwide. 
Epidemiology  
Following cardiovascular disease, cancer is the second most common cause 
of death for Americans (Jemal et al., 2010; Keating et al., 2011; Siegel et al., 2012; 
Wilson & Kizer, 1998). In fact, it is estimated that one in four deaths in the United 
States are due to cancer (Siegel et al., 2012). CRC and lung cancer are responsible 
for a tremendous portion of this disease burden. CRC is the third most commonly 
diagnosed cancer and the third leading cause of cancer-related death for both men 
and women (Siegel et al., 2012). Similarly, lung cancer is the second most 
commonly diagnosed cancer and the leading cause of cancer-related death for both 
genders (Siegel et al., 2012). It is expected that 226,160 Americans will be 
diagnosed with lung cancer, and 143,460 with CRC, in 2012 (Siegel et al., 2012).  
Over the past decade, overall cancer death rates have declined by 
approximately one percent annually for both African American and Caucasian men 
and women (Siegel et al., 2012). Death rates for both CRC and lung cancer are also 
declining (Siegel et al., 2012). Despite this improvement, the impact of cancer on the 
American population and U.S. healthcare systems is evident.  
Survival outcomes and treatment options are strongly associated with stage 
of disease at diagnosis. Staging for both CRC and lung cancer is generally based on 
either the American Joint Commission on Cancer (AJCC)(AJCC Cancer Staging 
Manual, 2002) or Surveillance, Epidemiology and End Results (SEER) summary 
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stage (Young, Roffers, Ries, Fritz, & Hurlbut, 2001). The AJCC staging system takes 
into account the number of tumors (T), lymph nodes positive for cancer (N), and 
metastases (M) present. The AJCC, or TNM, staging mechanism is most commonly 
used in clinical practice guidelines such as the NCCN guidelines (NCCN, 2011). 
Stages range from I to IV with IV indicating greater extent of disease and worse 
prognosis.  
A more simplistic method of staging is the SEER summary stage. SEER is a 
constellation of geographically based cancer registries that collect information on 
incidence, prevalence, and survival from approximately one-fourth of the nation 
(Young et al., 2001). The SEER summary stage categorizes the extent of disease 
into one of three categories—localized, regional, and distant (Young et al., 2001). 
Regardless of the staging mechanism used, staging assessments include a variety 
of clinical data inputs like tumor biopsies and imaging studies.  
Clinical Practice Guidelines 
Clinical practice guidelines are designed to help clinicians make appropriate 
diagnosis, treatment, and surveillance decisions. These guidelines may be 
evidence-based, consensus-based, or a combination thereof. Evidence-based 
guidelines are developed by systematically reviewing existing research results and 
scientific literature. Different levels of evidence, the highest of which is considered to 
be clinical trial data, may support evidence-based guidelines. In the absence of such 
high-quality data, consensus-based guidelines may be developed. Consensus-
based guidelines consider the limited evidence available but are largely based on 
the expert opinions of leaders in the field. A myriad of clinical practice guidelines, 
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both evidence- and consensus-based, exist to guide CRC and lung cancer treatment 
and surveillance. 
There are many established cancer clinical practice guidelines. Measures 
developed by the Association of Clinical Oncology (ASCO) and National Quality 
Forum (NQF), which are commonly applied in both clinical practice and health 
services research, were considered. In 2008, the NQF developed nineteen 
standardized performance measures assessing the quality of cancer care in several 
areas (including CRC), symptom management, and end of life care (National Quality 
Forum, 2011). The NQF measures are based on expert panel consensus of the 
American College of Surgeons Commission on Cancer. The ASCO quality measures 
were developed as part of the National Initiative on Cancer Care Quality (NICCQ). 
They encompass breast, colon, and rectal cancer care. Representatives of both 
ASCO and NCCN have collaborated to create joint measures. Measures were 
selected based on their ability to impact survival, opportunities for quality 
improvement efforts, and feasibility of data collection (Desch et al., 2008). These 
joint measures advance the field because of their versatility and potential for 
implementation in a wide variety of health systems. Despite the advantages of the 
ASCO/NCCN joint measures, they are focused on a finite group of cancers and, 
thus, are relatively narrow in scope. Therefore, this research uses guidelines 
developed by the NCCN. The NCCN measures are more sophisticated both in terms 
of the breadth of diseases addressed and the comprehensiveness of the guidelines.  
Although there is general agreement that timeliness of care is important, there 
is not much scientific evidence supporting specific timeliness of care guidelines 
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(Desch et al., 2008; Gould, Ghaus, Olsson, & Schultz, 2008; Pagano et al., 2010). In 
fact, at least one VA study found that timeliness of care had no measureable impact 
on lung cancer survival (Riedel et al., 2006). Despite this, the VA has made efforts to 
improve cancer care timeliness throughout the healthcare system, particularly for 
patients diagnosed with CRC (Powell, Nugent, Ordin, Noorbaloochi, & Partin, 2011). 
Measures of timeliness both for CRC (Aim 2) and NSCLC (Aim 3) are examined in 
this dissertation. 
Veterans Affairs (VA) Healthcare System 
History of the VA and Eligibility Process 
The VA healthcare system is a unique organization from which to gain insight 
into the issue of racial disparities in cancer care. It is the country’s largest integrated 
healthcare system (Goulet et al., 2007; McQueen, Mittman, & Demakis, 2004). In 
fact, VA healthcare is potentially available to 22.2 million veterans of service (Kizer, 
2012). It is also the largest provider of cancer care in the nation, treating 
approximately three percent of U.S. cancer cases nationwide (Zullig et al., 2012). 
Before the mid-1990s the VA was widely criticized for its overall organization 
and management, staffing, and the quality of care that it provided (Gardner, 1998; 
Holloway, Medendorp, & Bromberg, 1990; Perlin, 2006; Zook, Savickis, & Moore, 
1980). In fact, it was purported that the “VA [was] worried more about touting its 
performance measures and customer feedback then about improving actual quality 
of care” (Gardner, 1998). Rather than being an integrated health system, the 
Veterans Health Administration (VHA) was largely an organization of distinct VA 
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hospitals operating independently; this resulted in a fragmented system (Jackson & 
Weinberger, 2009; Jha, Perlin, Kizer, & Dudley, 2003).  
In response to these negative reports, in 1995 the VA began a system-wide 
transformation and redesign with emphasis on better using information technology 
systems, measuring and reporting quality of performance, and integrating services 
(Eisen & Francis, 2010; Jha et al., 2003). One of the key elements in the system 
redesign was the transition from independent medical centers into geographically 
based Veterans Integrated Service Networks (VISNs). These VISNs were developed 
to integrate policies, planning, and health services delivery among multiple VA 
hospitals. The VA has divided itself into twenty-two geographically arranged VISNs. 
These VISNs provide governance to ensure that quality improvement efforts and 
policies are enforced consistently and systematically. Furthermore, the VA also 
established Community Based Outpatient Clinics (CBOCs) that increased access to 
care by placing primary care providers in more diverse geographic areas (Jackson & 
Weinberger, 2009; Jha et al., 2003; Kizer & Dudley, 2009). 
In addition to making structural changes, the VA also renewed its focus on 
health information technology and quality measurement. The Computerized Patient 
Record System (CPRS) is the VA’s electronic health record (EHR). CPRS, which 
originated in 1997, is now considered one of the most advanced EHR systems in the 
United States (Jackson & Weinberger, 2009). CPRS includes the comprehensive 
clinical and demographic information required to provide high-quality patient care, 
data such as provider notes, medication information, imaging studies, and laboratory 
reports, among others. It also provides a platform for a robust clinical reminder 
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system that can facilitate care coordination and enhanced communication between 
patients and their care team (Jackson et al., 2011). Importantly, CPRS data is used 
extensively for quality measurement at the VA patient population level.  
The redesigned VA system has been credited with emphasizing a balance of 
cost, access, and quality (Wilson & Kizer, 1998), which has had positive 
ramifications for the VA. A recent study of older adults indicated that in most aspects 
VA cardiovascular and cancer care is equal or superior to care in the private sector 
(Keating et al., 2011; Trivedi & Grebla, 2011). Much effort has been focused on 
quality improvement. For example, improving CRC cancer screening, diagnosis, and 
treatment within VA has been given great emphasis (Jackson, Powell, et al., 2010). 
National learning collaboratives, CRC toolkits, screening directives, and similar 
national VA projects have had considerable impact on improving the overall quality 
of CRC treatment in the VA. Scientific literature assessing CRC care in the VA found 
that rates of guideline-concordance ranged from a low of approximately 44% of 
patients receiving guideline-appropriate surveillance colonoscopy to nearly 83% of 
patients receiving a preoperative carcinoembryonic antigen (CEA) prior to surgical 
resection (Jackson, Melton, et al., 2010). 
The high rates of cancer guideline adherence are, in part, due to the VA’s 
focus on cancer quality measurement and its extensive oncology services. Mirroring 
the general population, cancer is the second highest cause of morbidity and 
mortality for the nation’s veterans (Keating et al., 2011; Wilson & Kizer, 1998). As a 
result, the VA provides extensive oncology benefits to its patients and has 
considerable infrastructure to support this care. The VA system has approximately 
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140 hospitals. Of these hospitals, 132 host cancer registries, 60 have cancer 
programs that are approved by the American College of Surgeons Commission on 
Cancer (Keating et al., 2011), and 42 are designated as comprehensive cancer care 
centers (Keating et al., 2011; Wilson & Kizer, 1998). This cancer care infrastructure 
gives the VA the ability to provide care to nearly 40,000 newly diagnosed patients 
with cancer who receive care in the VA annually (Zullig et al., 2012). Given the 
breadth of the VA’s large cancer patient population, the potential impact of the VA on 
the overall quality of the nation’s cancer care is substantial. 
The affordability, range of services, and quality of care provided in the VA 
make it appealing to many patients. To access VA healthcare, veterans must first 
qualify to receive care. Eligibility for most VA health care benefits is based on active 
military service in the Army, Navy, Air Force, Marines, or Coast Guard with an 
honorable discharge. Members of the Reserve or National Guard may also qualify 
for VA healthcare if they were called into active service. Under certain 
circumstances, veterans’ dependents or surviving spouse may also be eligible to 
receive care in the VA. Upon entering the VA healthcare system, patients undergo a 
financial assessment (i.e., means test) and a service-connected status will be 
determined. Depending on the patient’s previous calendar year gross household 
income and net worth, patients are categorized according to income threshold for 
their geographic region. This categorization, in tandem with the service-connected 
status, is used to determine how much a patient will be charged in the form of co-
pays for the care they receive in the VA. Many patients, such as those who received 
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a Purple Heart Medal, former prisoners of war, or low-income veterans, will receive 
healthcare completely free through the VA system (Veterans Affairs, 2009).  
Veterans may be exempt from billing for additional reasons. Care for service-
connected disabilities is often provided at no cost to the patient. Service connection 
essentially means that there is evidence that “a particular injury or disease resulting 
in disability was incurred coincident with service in the Armed Forces” (Veterans 
Affairs, 2011). Veterans with preexisting conditions that were aggravated by their 
military service may also qualify for service-connected status. These may be both 
physical and mental conditions. Some cancers are considered to be service 
connected, due to working conditions or environmental or chemical exposures 
(Veterans Affairs, 2002).  
As a result of the eligibility process and sliding scale of fees, the VA is 
considered an equal access system (Dominitz et al., 1998; Rabeneck, Souchek, & 
El-Serag, 2003; Saha et al., 2008). Once a patient enrolls in the VA healthcare 
system they are granted access to affordable, high-quality care. In fact, the quality of 
care in the VA is consistently evaluated to be equal to or better than the private 
sector (Keating et al., 2011; Kizer & Dudley, 2009; Trivedi & Grebla, 2011; Trivedi et 
al., 2011). The VA’s distinctive organizational structure, diverse patient population, 
and availability of comprehensive data sources make in an ideal setting in which to 
assess racial disparities in timeliness and quality of cancer care.  
Importance of the VA to Health Services Research 
Because of VA patients’ unique qualification process, users of the VA 
healthcare system are not representative of the general U.S. population. Users of 
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VA healthcare are more likely to have poor health status, to have lower levels of 
education and income, to be African American, and to have higher rates of 
psychiatric illnesses and other disabilities (Agha, Lofgren, VanRuiswyk, & Layde, 
2000; Jha et al., 2003). In short, VA patients tend to be more comparable to patients 
seeking care in the community setting rather than at academic institutions. Despite 
limitations in terms of both patient- and system-level generalizability, the VA makes 
a notable contribution to national health services research. As the United States 
moves toward national health care reform, there are many important lessons that 
can be learned by studying the VA. The VA has a longstanding history as an ACO, 
which uses patient-centered medical homes (PCMH). More important, because of 
the large number of veterans prepared to receive VA care, the VA will have to 
develop strategies to integrate patients efficiently. The United States will undergo a 
similar transition as it extends healthcare access to 30 million Americans (An act 
entitled The Patient Protection and Affordable Care Act, 2010). The VA can serve as 
a model for this process. 
Race/Ethnicity Differences in CRC 
Evidence of racial disparities exists across the continuum of cancer care 
services—from diagnosis, to treatment, to surveillance and survival (Zapka et al., 
2003). Although a few isolated studies have found no difference (Bradley et al., 
2001; Schwartz et al., 2003), there is vast evidence that African Americans present 
with more advanced stages of disease than Caucasians (Berry et al., 2009; Jemal et 
al., 2010; Polite et al., 2005; Robinson et al., 2010; Siegel et al., 2012). Differences 
in stage at diagnosis may be a result of variances in screening patterns between 
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patients of minority and majority race. In the Medicare population, African Americans 
are 20% less likely to undergo a CRC screening colonoscopy and 40% less likely to 
undergo a flexible sigmoidoscopy than Caucasian patients (Richards & Reker, 2002; 
Robinson et al., 2010). Exacerbating this problem, African Americans have a higher 
proportion of right-sided cancers; right-sided cancers may be difficult to detect using 
common screening practices like flexible sigmoidoscopy which begin on the left side 
of the colon. This may inhibit early detection of CRC (Johnson & Carstens, 1986; 
Sabounchi et al., 2012; Shavers, 2007). This is because right-sided cancers, which 
occur in the ascending segment of the colon, are more difficult for physicians to 
reach with the colonoscope making detecting CRC during screening difficult. 
Perhaps as a result of differences in screening patterns, symptoms at CRC 
diagnosis also differ between races. African Americans present more frequently with 
rectal bleeding, heme-positive stools, and anemia (Sabounchi et al., 2012). 
Late presentation at diagnosis may be reduced in the VA because the VA 
offers access to preventive care services, such as CRC screening, and integrated 
care without the financial burden often experienced in the private sector. In fact, a 
recent national study of veterans determined that over 80% of patients receiving VA 
healthcare received some form of CRC screening (Long et al., 2012). This is much 
higher than the approximately 60% of Americans screened in the general population 
(Center for Disease Control and Prevention, 2008). Moreover, most veterans were 
being screened using colonoscopy, which is the gold standard technique for CRC 
screening (Long et al., 2012). Again, the story of racial differences in CRC screening 
is complex. Several studies have showed equal rates of CRC screening and, in 
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some cases, similar proportions of surgery and chemotherapy among patients of 
minority and majority races in the VA and, to a lesser extent, in the private sector 
(Dolan et al., 2005; Dominitz et al., 1998; Gornick, Eggers, & Riley, 2004; Robinson 
et al., 2010; Sabounchi et al., 2012). However, some of these studies have focused 
one VA medical center, thus limiting generalizability of findings to the VA system as 
a whole (Robinson et al., 2010; Sabounchi et al., 2012). Although these results are 
important, it is possible that practices across VA medical centers nationwide may 
differ. 
Even after receiving a cancer diagnosis, there is evidence that patients of 
different races may receive different cancer treatment. African American patients 
often have more comorbid conditions, which may contraindicate receipt of adjuvant 
chemotherapy (Ayanian et al., 2003; Morris et al., 2008). Although at least one study 
shows racial equality in receipt of chemotherapy (Landrum, Keating, Lamont, 
Bozeman, & McNeil, 2012), the majority of evidence shows that even after 
controlling for comorbidities African Americans remain 10% less likely to receive 
adjuvant therapy for Stage II CRC (Baldwin et al., 2005; Govindarajan et al., 2003; 
Sabounchi et al., 2012; Schrag et al., 2001). Similarly, African Americans are two 
times less likely to get surgery for Stage I and are also less like to get surgery for 
metastases of Stage IV CRC (Demissie et al., 2004). African Americans are also 
less likely to undergo radiation therapy and surgery for the treatment of rectal cancer 
(Ayanian et al., 2003; Govindarajan et al., 2003; Landrum, Keating, Lamont, 
Bozeman, Krasnow, et al., 2012; Landrum, Keating, Lamont, Bozeman, & McNeil, 
2012). Broadening the racial divide, refusal of cancer-related treatment is higher 
 22 
among African American patients with early stage CRC than among Caucasian 
patients (Demissie et al., 2004). 
After completing active treatment, patients transition into ongoing disease 
monitoring and surveillance. Adhering to surveillance guidelines is critical to detect 
potentially harmful recurrences and metastases. Compared to minority patients, 
Caucasians are more likely to undergo CEA surveillance after completion of CRC 
treatment (Elston Lafata, Cole Johnson, Ben-Menachem, & Morlock, 2001).  
There are significant racial differences in five-year survival rates as well. 
Though CRC mortality rates are universally decreasing across all racial groups, 
racial disparities in CRC mortality rates have progressively increased (Berry et al., 
2009; Siegel et al., 2012). Despite a few studies finding data to the contrary 
(Govindarajan et al., 2003; Robinson et al., 2010; Sabounchi et al., 2012), there are 
worse relative five-year survival rates for African Americans with CRC compared to 
Caucasian patients in both the private sector (Alexander et al., 2004; Dayal, 
Polissar, Yang, & Dahlberg, 1987; Govindarajan et al., 2003; Siegel et al., 2012) and 
the VA populations (Alexander et al., 2007; Dominitz et al., 1998). 
Race/Ethnicity Differences in Lung Cancer Care 
As in CRC, racial differences in lung cancer span from diagnosis, to active 
treatment, through patient outcomes. Unlike CRC, there are no effective screening 
techniques to detect lung cancer and, as such, many lung cancer patients present 
with advanced disease at diagnosis (Dransfield, Lock, & Garver, 2006). Treatment 
options for lung cancer are limited relative to CRC. Surgical resection is the only 
treatment modality that offers the potential of a cure (Dransfield et al., 2006). 
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However, many lung cancer patients are not suitable surgical candidates because of 
metastatic disease, comorbid conditions such as cardiovascular disease, and limited 
pulmonary function, all of which are clinical contraindications for surgery (Beckles, 
Spiro, Colice, & Rudd, 2003; Dransfield et al., 2006; Iizasa et al., 2004; Landrum, 
Keating, Lamont, Bozeman, & McNeil, 2012). As a result, lung cancer surgical 
resection rates in the United States remain quite low at an estimated 30% or less 
(Dransfield et al., 2006; Fry, Menck, & Winchester, 1996). 
There has been some evidence of racial equality of lung cancer care 
(Dransfield et al., 2006), but there is general consensus that rates of surgical referral 
(Lathan, Neville, & Earle, 2006), completion of surgery, and timeliness of lung 
cancer treatment vary by race (Bach, Cramer, Warren, & Begg, 1999; Farjah et al., 
2009; George & Margolis, 2010). One recent national VA study found conflicting 
results. Patients of diverse races with Stages I and II lung cancer were equally likely 
to be referred to a surgeon in the VA, but African American patients were less likely 
to be evaluated by the surgeon and, subsequently, were less likely to be 
recommended for surgery (Landrum, Keating, Lamont, Bozeman, & McNeil, 2012). 
There are also differences in wait times to undergo lung cancer surgical 
resection. In general, there is evidence that median wait times from diagnosis to 
treatment are on the rise for both CRC and lung cancer (Bilimoria et al., 2011). 
Among lung cancer patients, those diagnosed at earlier stages tend to have longer 
wait times for cancer care (Bilimoria et al., 2011; Powell et al., 2008). Racial 
differences in wait times exist as well, and the reasons for this are multifaceted. 
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There is qualitative indication that cultural and racial differences in patient 
perspectives surrounding lung cancer surgery may impact timeliness of care. African 
American patients often question the efficacy of surgery and, furthermore, believe 
that exposure of a cancerous tumor to air during the surgical procedure may cause 
the tumor to spread (George & Margolis, 2010). Conversely, Caucasian patients 
tend toward impatience with surgical wait times (George & Margolis, 2010). These 
racial differences in perspectives of surgery persist after controlling for income, 
education, gender, and other potentially confounding covariates. Additionally, African 
American patients are more likely to refuse lung cancer surgical resection (George & 
Margolis, 2010; Landrum, Keating, Lamont, Bozeman, Krasnow, et al., 2012; 
Margolis et al., 2003). Differences in cultural views about lung cancer surgery and in 
patient-provider trust may exacerbate racial differences in receipt of appropriate, 
timely lung cancer treatment. 
One VA study of African American and Caucasian lung cancer patients found 
that patient-reported levels of trust in their physician were equal before their visit, but 
after the visit African Americans reported lower levels of trust in their physician than 
their Caucasian counterparts. Moreover, African American patients reported that 
communication with their physician was less informative, less supporting, and less 
partnering than similar Caucasian patients (Gordon, Street, Sharf, Kelly, & Souchek, 
2006). Although these issues of patient perception are outside the realm of this 
dissertation, it is worth noting that there may be patient-initiated delays that affect 
lung cancer care timeliness and therefore subsequent survival rates. 
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Lung cancer is a fairly grim disease. The overall five-year survival rate across 
all stages of disease and races is approximately 16% (Siegel et al., 2012). As with 
CRC, survival for lung cancer is largely based dependent upon stage at diagnosis. In 
addition, receipt of surgical resection also has a dramatic impact on survival. For 
example, a single-site VA study found that patients with Stage IA lung cancer had an 
80% survival rate (Dransfield et al., 2006). 
The relationship between timeliness of lung cancer care and subsequent 
survival rates is complex (Olsson, Schultz, & Gould, 2009), perhaps because lung 
cancer patients diagnosed at earlier stages tend to have longer wait times for cancer 
care (Bilimoria et al., 2011; Powell et al., 2008). Several studies have shown that 
there is no association between timeliness of care and survival (Aragoneses, 
Moreno, Leon, Fontan, & Folque, 2002; Pita-Fernandez, Montero-Martinez, Pertega-
Diaz, & Verea-Hernando, 2003; Quarterman, McMillan, Ratcliffe, & Block, 2003; 
Salomaa, Sallinen, Hiekkanen, & Liippo, 2005), while others report that shorter times 
to treatment are associated with improved survival (Buccheri & Ferrigno, 2004; 
Kanashiki et al., 2003; Kashiwabara et al., 2003), and still other studies have found 
that longer times to treatment negatively impact patient outcomes (Annakkaya et al., 
2007; Comber, Cronin, Deady, Lorcain, & Riordan, 2005; Salomaa et al., 2005). 
However, there are dramatic differences in lung cancer five-year survival rates by 
race for patients that do not undergo surgical resection, with Caucasians surviving at 
a higher percentage than African Americans (Farjah et al., 2009; Siegel et al., 2012). 
In short, findings of racial disparities are somewhat mixed depending on the 
element of care examined (i.e., surgery, chemotherapy), the setting of care (i.e., 
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private, VA, urban, rural), and the specific population of patients being studied 
(Alexander et al., 2007). Examining racial disparities in a large national cohort of 
veteran patients, as examined in this dissertation, provided a complement to and 
advantage over much of the existing literature. 
Race/Ethnicity Differences in CRC and Lung Cancer Survival 
The American Cancer Society reported that from 2000 to 2007, African 
American patients were diagnosed at later stages than their Caucasian counterparts 
(Table 1) (Siegel et al., 2012). Moreover, five-year relative survival rates were lower 
for African Americans at every stage of diagnosis for CRC, lung, and many other 
cancer types (Pulte et al., 2012; Siegel et al., 2012).
Table 1. 
 
Stage Distribution and Five-Year Survival Rates by Stage at Diagnosis for Colorectal 
and Lung Cancers. (Siegel et al., 2012) 
 
 Colon & Rectum Lung & Bronchus 
 Stage 
Distribution 
Five-Year 
Survival 
Stage 
Distribution 
Five-Year 
Survival 
 Caucasian AA Caucasian AA Caucasian AA Caucasian AA 
Localized 39% 35% 91% 85% 15% 12% 53% 44% 
Regional 37% 34% 69% 64% 22% 22% 24% 22% 
Distant 19% 24% 12% 9% 55% 60% 4% 3% 
 
 
These data support the existence of racial disparities, which may arise from 
differences in access to care, receipt of quality cancer care, and/or patients’ 
underlying comorbid conditions (Siegel et al., 2012).  
It is important to note that overall survival rates are better in the VA 
healthcare system compared to fee-for-service SEER-Medicare patients. Landrum 
and colleagues compared all-cause and cancer-specific mortality rates among VA 
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and fee-for-service Medicare patients and found that, for both colon and NSCLC, 
survival rates were higher in among patients receiving care in the VA healthcare 
system (Landrum, Keating, Lamont, Bozeman, Krasnow, et al., 2012). Survival rates 
were similar for both groups of rectal cancer patients (Landrum, Keating, Lamont, 
Bozeman, Krasnow, et al., 2012). This improved survival rate may be because VA 
patients tend to be diagnosed with earlier stage disease, which often leads to better 
patient outcomes (Zullig et al., 2012).  
 
 CHAPTER 3: STUDY DESIGN AND METHODS 
Overview and Rationale 
This study was a secondary analysis of data collected for ongoing care quality 
measurement and performance efforts and administrative data. The study employed 
a retrospective design using EPRP data to identify men diagnosed with primary CRC 
and NSCLC receiving cancer care in the VA healthcare system. The binary 
dependent variables of interest were receipt of NCCN guideline-adherent colorectal 
cancer care, timeliness of receipt of colorectal cancer care and subsequent all-cause 
mortality, and timeliness of receipt of NSCLC care and subsequent all-cause 
mortality. The key explanatory variable is race. Analyses examine the association 
between race and guideline-concordance/timeliness controlling for regional 
characteristics, health status characteristics, and other independent covariates.  
Conceptual Framework 
In the context of observational, retrospective research studies, a conceptual 
model facilitates the identification of areas for potential system failure and future 
intervention. Racial disparities in quality and timeliness of cancer care are largely a 
function of three overarching factors: 1) healthcare system factors, 2) patient-level 
factors, and 3) the interaction between patient- and system-level factors.  
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Figure 1. A conceptual model depicting the role of patient, disease, and healthcare 
characteristics on the receipt of guideline-adherent and timely cancer care and 
subsequent health outcomes. 
 
The Chronic Care Model (CCM) was developed to help health systems 
change their standard delivery of care practices through system redesign. The 
compilation of these practice-changing efforts results in a patient-centered, 
evidence-based healthcare system that proactively provides population-based care 
(Coleman, Austin, Brach, & Wagner, 2009; Wagner et al., 2001; Wagner et al., 
2005). Wagner and colleagues purport that most healthcare systems have been 
designed to treat acute illnesses rather than for ongoing management and 
coordination of care for patients with chronic conditions. Given the dramatic rise in 
chronic conditions, including cancer, the complexity and integration of services 
required to provide high-quality care are often inadequate within healthcare systems. 
Broadly, healthcare systems are often fragmented, poorly organized, and 
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constrained by modern information technology (America & Medicine, 2001; Wagner 
et al., 2001; Wagner et al., 2005). 
Wagner and colleagues assert that “high-quality chronic illness care is 
characterized by productive interactions between practice team and patients” 
(Wagner et al., 2001). The authors state that effective healthcare systems ensure 
access to timely and relevant data on both individual patients and patient 
populations based on clinical information systems like electronic health records and 
disease registries (Wagner et al., 2001). Moreover, the CCM contains six 
elements—the healthcare organization, community resources, self-management 
support, delivery system design, decision support, and clinical information systems. 
These six elements inform our examination of racial disparities in cancer care quality 
and timeliness in the integrated VA healthcare system. 
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Figure 2. Chronic care model. Adapted from Wagner and colleagues, 2005. (Wagner 
et al., 2005) 
 
Research Questions and Hypotheses 
Research Question 1: Do patient-level factors, such as race, affect the odds 
of receiving NCCN guideline-adherent CRC care, controlling for known covariates? 
H1: African American race will be associated with reduced odds of receiving 
guideline-adherent CRC care compared to Caucasian race after controlling for 
known covariates. 
Research Question 2a: Do patient-level factors, like race, affect the timing of 
receipt of CRC care, controlling for known covariates? 
H2a: African American race will be associated with longer times to CRC care 
compared to Caucasian race after controlling for known covariates. 
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Research Question 2b: Do patient-level factors, like race, affect all-cause 
mortality among CRC patients, controlling for known covariates? 
H2b: African American race will be associated with higher all-cause mortality 
than Caucasian race among CRC patients, controlling for known covariates. 
Research Question 3a: Do patient-level factors, like race, affect the timing of 
receipt of lung cancer care, controlling for known covariates? 
H3a: African American race will be associated with longer times to CRC care 
compared to Caucasian race, controlling for known covariates. 
Research Question 3b: Do patient-level factors, like race, effect all-cause 
mortality among lung cancer patients, controlling for known covariates? 
H3b: African American race will be associated with higher all-cause mortality 
than Caucasian race among lung cancer patients, controlling for known covariates. 
Data 
This dissertation relies on several data sources including two distinct EPRP 
data sets assessing quality of care for CRC and lung cancer patients. This EPRP 
data was supplemented with administrative data that will be obtained from the 
Veterans Affairs Informatics and Computing Infrastructure (VINCI) warehouse. An 
explanation of each of these data sets is provided below. 
The EPRP was authorized by Congress and the VA to provide quality of care 
information that can be used by the VA for quality improvement, evaluation, and 
benchmarking with external organizations (Kussman, 2008). Data are manually 
abstracted from CPRS, the VA’s electronic health record, and paper shadow charts. 
A contracting, non-federal agency conducts the data collection. The West Virginia 
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Medical Institute (WVMI), under the auspices of the VA Office of Quality and 
Performance (OQP), has conducted the data collection for both the CRC and lung 
cancer EPRP datasets (Jackson, Melton, et al., 2010). These data represent 
substantial investment for the VA healthcare system (Goulet et al., 2007), both in 
terms of a financial and labor commitment. EPRP selects a random sample of VA 
patients nationwide that were treated or diagnosed with a specific condition in a 
given fiscal year (Goulet et al., 2007; Kussman, 2008).  
Quality measurement and improvement is the central focus of EPRP. As 
such, patients are not asked to provide consent for participation in the medical 
record review process. Individual research projects may use EPRP data and link 
with additional administrative and other datasets as indicated in IRB-approved 
protocols (Goulet et al., 2007). 
Although EPRP lung cancer data contains information about patients’ 
comorbidity and vital status, the EPRP CRC data does not contain this data. 
Therefore, the EPRP CRC data set will be supplemented with administrative data 
from the VINCI warehouse to create a comprehensive data set containing 
information on patients’ comorbidity and vital status. 
VINCI is a nontraditional data warehouse. VINCI is a mechanism through 
which VA researchers and operations can request access to myriad data sets. VINCI 
houses administrative data sets like the Corporate Data Warehouse (CDW), the 
Medical SAS files, and the Decision Support System (DSS). The CDW contains vital 
signs, clinical reminders, and consultation data. The Medical SAS data sets include 
inpatient and outpatient treatment information, and the DSS encompasses 
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laboratory values, health service utilization information, and healthcare costs. VINCI 
also includes other data sources such as EPRP.  
 VINCI provides a secure, high-performance computing environment for VA 
researchers to access administrative data. The data requested from VINCI 
contained comorbidity information necessary to determine a comorbidity index 
score, which was used in all analyses (Klabunde, Legler, Warren, Baldwin, & 
Schrag, 2007). The presence of specific comorbid conditions may impact patients’ 
ability to tolerate certain cancer treatments. Moreover, these comorbidities may 
affect clinical decision making regarding receipt of certain chemotherapeutic agents 
and other aspects of cancer care (Carpenter et al., 2012). For example, sensory 
neuropathy is a known side effect of oxaliplatin (Koopman & Punt, 2009). A patient 
with a low comorbidity index score (i.e., lower score indicates better health) might 
still not be a good candidate to receive oxaliplatin if they already suffer from diabetic 
neuropathy. Therefore, comorbidity was measured in two ways—using the NCI 
Combined Comorbidity Index, and by considering individual health conditions that 
comprise the index (Klabunde et al., 2007). 
In an effort to ensure that data for analysis was timely, patients’ vital status 
information and date of death was also attained from VINCI. VINCI data are 
electronically extracted from administrative and medical records on a nightly basis, 
making this an ideal mechanism to attain accurate and current vital status 
information. 
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Figure 3. Dissertation data sources. Blue shading indicates that a data source was 
used in the dissertation. Data sources with white shading are provided for reference. 
 
The EPRP data sets were supplemented with information from the vital status 
file, which was obtained via VINCI. The data requested include current vital status 
(i.e., living or deceased) and, when applicable, the date of death. Comorbidity 
information, measured as an ACE-27 and Charlson Index, is already included in the 
lung cancer EPRP data set. Information needed to calculate a comorbidity score 
(i.e., ICD-9 codes) for the CRC EPRP cohort was obtained in the form of ICD-9 
scores from the Medical SAS files. This information was obtained through VINCI. 
In summary, this dissertation requires data obtained through VINCI from four 
primary sources: 1) the CRC EPRP data file, 2) the lung cancer EPRP data file, 3) 
the vital status file, and 4) the Medical SAS files (Figure 3). 
Study Sample and Inclusion/Exclusion Criteria 
The general description of the study inclusion criteria is provided below (Table 
2). 
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Table 2. 
 
Inclusion Criteria. 
 Inclusion Criteria 
Healthcare 
System 
Must have received some portion of their cancer care within 
the VA 
Cancer Diagnosis ICD-9 classification for cancer of the colon or rectum (Aims 1 
and 2) or lung (Aim 3) 
Diagnosis Time 
Window 
Diagnosed between October 1, 2003 and March 31, 2006 
(Aims 1 and 2); 
Diagnosed between October 1, 2006 and December 31, 
2007 (Aim 3) 
Cancer Stage Must be invasive (i.e., not in situ) and non-metastatic (i.e., 
not Stage IV) (Aims 1 and 2); 
Must have advanced disease (i.e., Stage III or IV) (Aim 3) 
Surgery Must have undergone surgical resection (Aims 1 and 2) 
Gender Male 
 
The study sample for Aims 1 and 2 includes patients diagnosed with incident 
CRC between October 1, 2003, and March 31, 2006 (Hynes, Perrin, Rappaport, 
Stevens, & Demakis, 2004; Jackson, Powell, et al., 2010). Patients must have been 
diagnosed with an International Classification of Disease (ICD-9) code for colon 
and/or rectal cancer (Perlin, Kolodner, & Roswell, 2004) between three months 
before and three months after the diagnosis during the study period. To further 
confirm a CRC diagnosis, eligible patients must have evidence of visiting one or 
more of the following VA medical services within three months before or after 
diagnosis: medical oncology, surgery, hospice, pathology, gastroenterology, and/or 
colonoscopy. Furthermore, patients had to have definitive surgical resection of their 
CRC and be diagnosed with Stage I, II, or III disease. The patients’ diagnosis dates 
were based on the date of a signed pathology report that indicated diagnosis of 
invasive CRC. A surgical pathology report date was recorded for all patients 
included in this study (Jackson, Powell, et al., 2010). Although men and women may 
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have different patterns of healthcare use (Friedemann-Sanchez, Griffin, & Partin, 
2007), the small number of women in the EPRP data did not enable statistical 
inferences about them. Therefore, all analyses are restricted to males.  
The study sample for Aim 3 includes patients with invasive NSCLC (Hynes et 
al., 2004). Patients for Aim 3 must have been diagnosed with advanced NSCLC (i.e., 
Stage III or Stage IV) between October 1, 2006, and December 31, 2007.  
Sample Size 
EPRP data for CRC (Aims 1, 2a, and 2b) and NSCLC (Aims 3a and 3b) were 
used to examine receipt of NCCN guideline-adherent and timely cancer care. For 
Aims 1 and 2, we used EPRP CRC data for patients diagnosed between October 1, 
2003, and March 31, 2006, with vital status and comorbidity follow-up through May 
2012. The vital status and comorbidity information were obtained through 
administrative data sources based on electronically extracted information from the 
VA electronic medical record. From previous studies using the EPRP CRC data set, 
we anticipated that 2,492 non-metastatic CRC patients will be available for 
analysis;(Jackson, Melton, et al., 2010) we estimated that: ~13% will be African 
American (n=326), 72% Caucasian (n=1,793), fewer than 1% from other minority 
races (n=16), and ~14% of unknown race (n=357) (Jackson, Melton, et al., 2010).  
Jackson and colleagues examined several overall quality measures using the 
EPRP CRC data set. Although they did develop models to identify patient or 
organizational characteristics associated with likelihood of receipt of guideline-
adherent, timely care, their work provided insight into the expected sample size per 
quality measure. For example, in Aim 1, from three of the outcome measures 
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(described in greater detail in the subsequent section)—preoperative CT scan of the 
abdomen and pelvis prior to definitive surgical resection, preoperative CEA 
determination prior to definitive surgical resection, and referral to a medical 
oncologist—approximately 1,729 cases are expected. The smallest expected 
sample size for a specific dependent variable is approximately 808 cases for a 
measure of adjuvant 5FU or capecitabine administered after definitive surgical 
resection (Jackson, Melton, et al., 2010). 
In Aim 2, we examined timeliness of CRC care. Elements of recommended 
care, such as receipt of adjuvant chemotherapy, are dictated based on a patient’s 
stage of disease (NCCN, 2011). Therefore, measuring time to care is dependent on 
patients receiving the two relevant elements of recommended care. Sample sizes for 
each timeliness measure varied depending on the number of relevantly staged 
patients. Based on previous work using the EPRP colorectal cancer data set, we 
anticipated the following sample sizes: days from diagnosis to initiation of treatment 
(n=1,729), days from definitive surgical resection to start of adjuvant chemotherapy 
(n=767), and days from definitive surgical resection to surveillance colonoscopy for 
colonoscopies performed at least 7 months after surgical resection (n=644) 
(Jackson, Melton, et al., 2010). 
Aim 3 used the EPRP NSCLC data set. EPRP NSCLC data for patients 
diagnosed between October 1, 2006, and December 31, 2007, with vital status and 
comorbidity follow-up through February 2010 were used. As for the colorectal cancer 
cohort, the vital status and comorbidity information were obtained through 
administrative data sources based on electronically extracted information from the 
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VA electronic medical record.  
There are no known published studies to date that use the EPRP NSCLC 
cancer data set to examine care among patients with advanced disease. However, a 
previously published report described cancer incidence in the VA as reported in the 
VA Central Cancer Registry (VACCR) in 2007 (Zullig et al., 2012). Following 
prostate cancer, the report identified lung cancer (n=7,437) as the second most 
commonly diagnosed cancer among male veterans. The report also described the 
racial distribution of VA lung cancer cases as follows: 19.7% Caucasian (n=6,118), 
15.5% African American (n=1169), and 15.4% other minority or unknown race 
(n=150) (Zullig et al., 2012). 
Variables and Measurement 
National Comprehensive Cancer Network Measures 
Constructing the NCCN measures requires a great deal of detailed staging 
and treatment information that may not be readily available in all healthcare 
systems. However, the VA’s nationwide electronic health record system and 
administrative data sources (Eisen & Francis, 2010; Jackson & Weinberger, 2009) 
give the VA the ability to assess a more comprehensive spectrum of measures than 
the ASCO/NCCN joint measures. In addition to the previously discussed measures, 
the NCCN measures were also considered for use as dependent variables for this 
dissertation. The benefit of NCCN guidelines is that they are based on scientific 
evidence when available and on the consensus of an expert panel when there is 
insufficient evidence to make a scientific recommendation (Cruse, Winiarek, 
Marshburn, Clark, & Djulbegovic, 2002; Jackson, Melton, et al., 2010; Winn, Botnick, 
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& Dozier, 1996). NCCN measures are divided into three categories of evidence and 
consensus. Category 1 represents the highest level of evidence, where there is 
uniform consensus based on high-level evidence that the intervention is appropriate. 
The quality of care measures examined in this dissertation have at least an NCCN 
evidence category of 2A, indicating that there is uniform consensus about the 
appropriateness of the intervention, but some of the evidence is lower level (NCCN, 
2011). 
Dependent Variables 
For Aim 1, the outcome variables of interest are binary indicators (whether or 
not the patient received guideline-concordant care). Six distinct quality metrics were 
used to describe guideline-concordant care (Table 3). An example metric is 
“documentation that radial margins were free of tumor at the time of definitive 
surgical resection.” Because stage of disease dictates appropriate care, each quality 
indicator had a distinct sample population.  
For Aims 2 and 3, the outcome variables were the number of days elapsed 
between two events derived from the manually abstracted medical records data in 
EPRP (Table 3). An example of a timeliness measure is the number of days 
between definitive surgical resection to start of adjuvant therapy. Time from surgical 
resection to death will be examined for both the NSCLC and CRC cohorts. Vital 
status and date of death, when applicable, will be obtained from VINCI. 
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Table 3. 
 
Outcome Variables and Measures. 
Aim Outcome Measure Variable Sample Population 
Aim 1 Preoperative CT scan of the 
abdomen and pelvis prior to 
definitive surgical resection. 
Binary  
 1=received 
 0=did not 
Stages II and III CRC 
Aim 1 Preoperative CEA 
determination prior to 
definitive surgical resection. 
Binary  
 1=received 
 0=did not 
Stages II and III CRC 
Aim 1 Documented radial margins 
were free of tumor at the time 
of definitive surgical 
resection. 
Binary  
 1=received 
 0=did not 
Stages II and III CRC 
Aim 1 Referral to a medical 
oncologist. 
Binary  
 1=received 
 0=did not 
Stages II and III CRC 
Aim 1 Adjuvant 5FU or capecitabine 
administered after definitive 
surgical resection. 
Binary  
 1=received 
 0=did not 
Stage III CRC 
Aim 1 Surveillance colonoscopy 
within 7 to 18 months after 
definitive surgical resection 
for patients with 
documentation of no 
preoperative obstructing 
lesion. 
Binary  
 1=received 
 0=did not 
Stages I, II, and III 
CRC with no 
preoperative 
obstructing lesion 
documented 
Aim 2a Days from definitive surgical 
resection to start of adjuvant 
chemotherapy. 
Count 
(number of 
days 
between 
events) 
Stages II and III CRC 
Aim 2a Days from definitive surgical 
resection to surveillance 
colonoscopy for 
colonoscopies performed at 
least 7 months after surgical 
resection. 
Count 
(number of 
days 
between 
events) 
Stages I, II, and III 
CRC with no 
preoperative 
obstructing lesion 
documented 
Aim 2b Days from definitive surgical 
resection to death. 
Count 
(number of 
days 
between 
events) 
Stages I, II, and III 
CRC 
Aim 3a Days from diagnosis to first 
treatment. 
Count 
(number of 
days 
Stages III and IV 
NSCLC 
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The quality indicator outcome measures for Aim 1 were derived from NCCN 
measures (NCCN, 2011).  
Though there is general agreement that timeliness of care is important, there 
is limited scientific evidence supporting specific timeliness of care guidelines (Desch 
et al., 2008; Gould et al., 2008; Pagano et al., 2010). In fact, at least one VA study 
found that timeliness of care had no measureable impact on lung cancer survival 
(Riedel et al., 2006). Despite this, the VA has made efforts to improve cancer care 
timeliness throughout the healthcare system, particularly for patients diagnosed with 
CRC (Powell et al., 2011). Measures of timeliness for both CRC (Aim 2) and lung 
cancer (Aim 3) were included in this dissertation. 
Key Independent Variables 
For each aim, the main independent variable of interest was race. Reflective 
of the racial composition of VA healthcare system users, the dissertation included 
race as a binary variable (i.e., Caucasian=1, African American=0). A more granular, 
categorical measure of race was not feasible due to the small numbers of patients 
within each minority group. An earlier manuscript using the EPRP CRC cohort 
between 
events) 
Aim 3a Days from diagnosis to 
referral to palliative care. 
Count 
(number of 
days 
between 
events) 
Stages III and IV 
NSCLC 
Aim 3b Days from diagnosis to death. Count 
(number of 
days 
between 
events) 
Stages III and IV 
NSCLC 
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reported that 72% of the patient cohort was Caucasian, approximately 13% were 
African American, and approximately 15% were of other minority or unknown race 
(Jackson, Melton, et al., 2010). Given the small numbers of patients of other minority 
races (i.e., not African American) this dissertation focuses on Caucasian and African 
American comparisons. The race variable will be based on the EPRP race, which 
used race as reported in the VACCR. A major strength of these VA data sources 
over Medicare or traditional other administrative data is the relatively low amount of 
missing race information.  
Control Variables 
The control variables are similar across all three aims. Patient characteristics, 
regional characteristics, and disease characteristics were included to control for their 
association with receipt of guideline-adherent, timely cancer care and subsequent 
health outcomes (Table 4).
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Table 4. 
 
Independent Variables and Measures. 
Construct Dimension Variable Data 
Source 
Patient 
characteristics 
Race (key independent) Caucasian (binary) EPRP 
 Age Age at diagnosis 
(categorical) 
EPRP 
 Social support Marital status 
(categorical) 
EPRP 
Regional 
characteristics 
Geographic area (i.e., 
VISN) 
West (binary) 
South (binary) 
East (binary) 
Central (binary) 
EPRP 
Health status Comorbid conditions NCI comorbidity index 
(categorical) 
Liver disease (binary) 
Renal disease (binary) 
Paralysis (binary) 
CHF or acute MI or 
CVD or COPD (binary) 
Neuropathy (binary) 
Diabetes (binary) 
VINCI 
 Cancer characteristics Stage of disease 
(categorical) 
EPRP 
Age 
Patients’ age at diagnosis was extracted from EPRP and used in all analyses. 
Current clinical guidelines do not contain upward age boundaries after which point 
patients should receive different or no care. For example, guidelines do not state 
that after age 90 a patient should no longer receive surveillance colonoscopy. 
Rather, guidelines stress the importance of assessing patients’ performance or 
functional status. However, there is evidence that patients who are older at the time 
of diagnosis may receive less cancer care, particularly in regard to adjuvant 
chemotherapy (Ayanian et al., 2003; Esnaola, Stewart, Feig, Skibber, & Rodriguez-
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Bigas, 2008; Potosky, Harlan, Kaplan, Johnson, & Lynch, 2002; White et al., 2008). 
This age disparity is well documented across several cancer types and healthcare 
settings despite there being no evidence that older people experience greater 
chemotherapy-related toxicity (Chang et al., 2011; Cronin et al., 2006; Kohne, 
Folprecht, Goldberg, Mitry, & Rougier, 2008; Scheithauer et al., 2003; Twelves et al., 
2005). 
Social Support 
Social support has been positively associated with receipt of high-quality care 
and better patient outcomes (Ayanian et al., 2003; Potosky et al., 2002). Adequate 
social support can be protective against traditional barriers to cancer care like having 
accessible transportation—a prerequisite for receipt timely and guideline-adherent 
care (Zullig et al., 2011). As a result, all analyses controlled for patients’ marital 
status as abstracted in the EPRP data. 
Geographic Area 
There is evidence of geographic variation in the delivery of high-quality 
cancer care (Egede et al., 2011; Potosky et al., 2002). In an effort to control for 
geographic orientation, the EPRP data set associates cases with their originating 
facility and VISN (Veterans Affairs, 2010). As previously discussed in Chapter 2, 
VISNs are the VA’s geographical divisions of the country. As a proxy for region, 
cases were assigned to a geographic quadrant based on VISN of origin (Figure 3). 
Specially, the Northern region was defined as VISNs 1, 2, 3, and 4. The Southern 
region was defined as VISNs 5, 6, 7, 8, 9, 16, and 17. VISNs 10, 11, 12, 15, and 23 
were considered as the Central region. Lastly, VISNs 18, 19, 20, 21, and 22 were 
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deemed the Western region. These regions are not equally distributed based on 
landmass or patient population, but approximate standard geographical divisions of 
the U.S. 
 
Figure 4. Veterans Integrated Service Network (VISN) map. 
Source: http://www2.va.gov/directory/guide/map.aspdnum=1 (Accessed Sept. 30, 
2011). 
 
Comorbid Conditions 
Comorbidities, including pre-existing chronic or acute conditions that are 
distinct from the primary illness of interest (Feinstein, 1970; Iezzoni et al., 1992), can 
affect clinical decision making, treatment options, and treatment outcomes. Patients 
with a higher number of, or more severe, comorbidities may be less likely to tolerate 
certain therapies, may be at greater risk of complications, and may be less 
responsive to treatment.  
Many comorbidity measures have been developed over the past 35 years. 
Choosing a comorbidity measure should reflect the research question, patient 
population, available data, validity, and feasibility. Perhaps the measure most widely 
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used by health services researchers and epidemiologists is the Charlson comorbidity 
index (Charlson, Pompei, Ales, & MacKenzie, 1987). Based on medical record 
review data, the Charlson Index creates a weighted measure that was predictive of 
one-year all-cause mortality. Many adaptations to the Charlson Index have been 
developed (Deyo, Cherkin, & Ciol, 1992; Klabunde et al., 2007; Klabunde, Potosky, 
Legler, & Warren, 2000). For example, Deyo and colleagues used ICD-9-CM 
procedural and diagnosis codes from hospital claims data in lieu of medical record 
data (Deyo et al., 1992). Notably, although the Deyo adaptation of the Charlson 
Index has been widely used, the majority of studies have been conducted with 
inpatients’ setting, thus limiting its utility in cancer, which includes substantial 
outpatient care.  
Another adaption of the Charlson is the Elixhauser Index (Elixhauser, Steiner, 
Harris, & Coffey, 1998). Elixhauser and colleagues expanded the Charlson to 
include thirty comorbid conditions with the aim of making the index applicable to a 
broader array of diseases. They included mental health problems, drug abuse, and 
alcohol abuse, to name a few. Unlike previous adaptations, Elixhauser did not create 
a summary score index but instead maintained separate metrics for each comorbid 
condition to enable customization to patients with specific diseases. However, this 
adaptation has not gained traction in the cancer health services research scientific 
literature. 
Based on the Charlson Index, Klabunde used data from Medicare Part B 
physician claims and customary hospital claims to create the NCI Index, which uses 
those data sources to calculate two separate comorbidity indices (Klabunde et al., 
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2000). Klabunde used a cohort of prostate and breast cancer patients to validate this 
NCI Index. As such, the authors used a different weighting procedure than the 
original Charlson index (Charlson et al., 1987). The list of comorbid conditions also 
differed. The NCI Index excludes diagnoses of solid tumors and metastases 
because the focus of the adapted comorbidity index is on non-cancer comorbidities. 
It therefore reduces the number of included conditions from the nineteen based on 
the original Charlson Index to sixteen conditions deemed relevant for a cancer 
patient population. In addition to changing the number of included comorbidities, the 
authors also demonstrated that condition weights differed by cancer site.  
A modified NCI Index has now been validated in the four most common 
anatomical cancer sites—breast, prostate, colorectal, and lung. This adaptation, 
called the NCI Combined Index (Klabunde et al., 2007), compressed the comorbidity 
scores into a single, unified comorbidity index score. The authors compared four 
analytic approaches to construct comorbidity indices and concluded that there is 
justification for using cancer site-specific weights when calculating comorbidity 
scores. In part, this is because certain comorbid conditions may have a pattern of 
multicollinearity with a specific type of cancer (Klabunde et al., 2007). The authors 
also stress the importance of including other baseline measures, like patient age and 
stage at diagnosis, to further underscore the implications of comorbidity index score. 
The NCI Combined Index has been a respected comorbidity index for cancer 
patients and others who receive care including both in- and outpatient settings.  
In addition to the Charlson comorbidity index and its myriad other adaptations 
(Charlson et al., 1987; Deyo et al., 1992; Klabunde et al., 2007; Klabunde et al., 
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2000), the ACE-27 relies on medical record data for its calculation (Fleming et al., 
2011; Piccirillo, Creech, Zequeira, Anderson, & Johnston, 1999). The ACE-27 
includes twenty-six comorbid conditions and three grades of severity. Some studies 
have shown the ACE-27 to be more accurate than the Charlson in predicting 
mortality in groups of critically ill patients (Pinckney, O'Brien, Piccirillo, & Littenberg, 
2004; Soares et al., 2005). However, its reliance on medical record data has limited 
its feasibility and widespread adoption. A recent study developed a Medicare claim–
based version of the ACE-27 measures using a breast and prostate cancer cohort. 
The study found higher reporting of comorbidities in medical records compared with 
Medicare claims data, however the sensitivity was approximately 80% (Fleming et 
al., 2011). 
After careful consideration, the NCI Combined Index was favored for all 
analyses throughout the dissertation. This is because: (1) it has been validated in 
different groups of patients with cancer; (2) a cancer-specific measure is likely to be 
more meaningful than generic measures; and (3) the data to calculate this index are 
available. 
Recent literature has illustrated the importance of considering not only a 
patient’s overall comorbidity index score but also the presence of specific comorbid 
conditions that may impact one’s ability to withstand cancer treatments. Specific 
comorbid conditions may influence clinical decision making (Carpenter et al., 2012). 
As previously described, chemotherapeutic agents like oxaliplatin have documented 
clinical side effects such as sensory neuropathy (Koopman & Punt, 2009). A patient 
suffering from diabetic neuropathy may not be a strong candidate for oxaliplatin even 
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with an otherwise low comorbidity index score (i.e., lower score indicates better 
health). Because of these important factors, comorbidity was measured in two 
ways—by using the NCI Combined Comorbidity Index and by considering individual 
health conditions that comprise the index (Klabunde et al., 2007). Specific conditions 
are listed in Table 5. Relevant diagnostic codes for this analysis primarily came from 
the ICD-9-CM (Table 5) (Corporation, 2006).
Table 5. 
 
ICD-9-CM Codes Used to Identify Comorbid Conditions. 
Condition ICD-9 Diagnosis Codes ICD-9 Procedural Codes 
Myocardial infarction "410" - "41099"  
Old myocardial 
infarction  
"412" - "41299"  
Congestive heart failure  "428" - "42899"  
Peripheral vascular 
disease  
"441" - "44199", "4439"-
"44399", "7854"-"78549", 
"V434" 
"3813","3814","3816","381
8","3843","3844","3846", 
"3848","3833","3834","383
6","3838","3922"-
"3926","3928","3929" 
Cerebrovascular 
disease  
"430" - "438" "3812", "3842" 
Chronic obstructive 
pulmonary disease  
"490" - "49699", "500"-
"50599", "5064"-"50649" 
 
Paralysis  "342" - "34299", "3441"-
"34419" 
 
Diabetes  "250", "2500"-"25039", 
"2507" - "25079" 
 
Diabetes with sequelae "2504" - "25069", "2508"-
"25099" 
 
Chronic renal failure "582" - "58399", "585"-
"58699", "588"-"58899" 
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Various cirrhodites  "5712" -"57129", "5714"-
"57169" 
 
Moderate-severe liver 
disease 
"5722" - "57289", "4560"-
"45619", 
"4562","45620","45621" 
"391", "4291" 
Ulcers "5310" - "53139", "5320"-
"53239", "5330"-"53339", 
"5340"-"53439", "531", 
"5319"-
"53199","532","5329"-
"53299","533","5339"-
"53399","534","5349"-
"53499", "5314" - 
"53179", "5324"-
"53279","5334"-
"53379","5344"-"53479" 
 
Rheumatoid Arthritis "71481", "725", "7100", 
"7101", "7104", "7140"-
"71429" 
 
Stage 
AJCC stage was included as a control variable in all analyses (AJCC Cancer 
Staging Manual, 2002). Stage is one of the first inputs involved in determining where 
a patient falls within the NCCN guidelines (NCCN, 2011). Patients were included in 
specific guideline-adherence analysis based on their stage at diagnosis. The AJCC 
staging for lung and CRC is described in Table 6. Because diagnosis and treatment 
patterns are dramatically different for patients with non-invasive cancers, stage 0 
(i.e., in situ) patients were excluded from all analyses (NCCN, 2011). 
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Table 6. 
 
Lung and Colorectal Cancer Staging. 
Colorectal Cancer 
AJCC Stage Description 
Stage 0* Tis: Tumor confined to mucosa; cancer-in-situ. 
Stage I T1: Tumor invades submucosa. 
Stage I T2: Tumor invades muscularis propria. 
Stage II-A T3: Tumor invades subserosa or beyond (without other organs involved). 
Stage II-B T4: Tumor invades adjacent organs or perforates the visceral peritoneum. 
Stage III-A N1: Metastasis to 1 to 3 regional lymph nodes. T1 or T2. 
Stage III-B N1: Metastasis to 1 to 3 regional lymph nodes. T3 or T4. 
Stage III-C N2: Metastasis to 4 or more regional lymph nodes. Any T. 
Stage IV M1: Distant metastases present. Any T, any N. 
Lung Cancer 
AJCC Stage Description 
Stage 0 Tis: Tumor confined to mucosa; cancer-in-situ. 
Stage IA T1a–T1b: Tumor 3 cm or less in greatest dimension. 
Stage IB T2a: Tumor more than 3 cm but less than 5 cm in greatest dimension. 
Stage IIA Tumor more than 3 cm and less than 7 cm in greatest dimension; may be nodal involvement. 
Stage IIB Tumor between 5 cm and 7 cm; tumor may directly invade the parietal pleural, chest wall, and other adjacent areas. 
Stage IIIA 
Tumor of any size that invades the mediastinum, heart, 
great vessels, and other adjacent areas; may be nodal 
involvement. 
Stage IIIB 
Tumor of any size that invades the mediastinum, heart, 
great vessels, and other adjacent areas; with nodal 
involvement. 
Stage IV M1: Distant metastases present. Any T, any N. 
Adapted from: http://www.cancerstaging.org/staging/posters/lung8.5x11.pdf 
(Accessed 10/2/2011). 
*Patients with Stage 0 are excluded from all analyses. 
 
Statistical Analyses by Aim 
Summary statistics were reviewed before running regression models to determine 
proportions and means of patient demographics and disease characteristics across 
the sample. The summary statistics were stratified by race (i.e., Caucasian and 
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African American). Statistical significance of differences in study variables between 
the two time periods were assessed using t-tests for continuous variables and chi-
square tests for categorical variables (Wooldridge, 2008). Statistical significance was 
set between 0.01 and 0.05, as indicated in each specific analysis. 
Aims 1, 2a, and 2b were examined using the EPRP colorectal cancer data. In 
Aim 1, multivariate logistic regression with odds ratios was used for each binary 
dependent variable (Table 3) (Hosmer & Lemeshow, 2000). The appropriateness of 
including specific interaction terms (i.e., race*age, race*comorbidity score) was 
assessed by examining changes in the likelihood ratio (LR) test statistic and Wald 
test statistics (Mickey & Greenland, 1989). Likelihood ratio test statistics were also 
used to examine the suitability of using clustered standard errors and, similarly, 
Huber-White robust standard errors to adjust for heteroskedasticity. Previous 
research has illustrated the importance of adjusting for multiple factors (i.e., 
demographic information and comorbidities) simultaneously when examining racial 
disparities (Jean-Jacques, Persell, Hasnain-Wynia, Thompson, & Baker, 2011). 
Therefore, adjusted predicted probabilities were examined. A threshold of 0.01 was 
used to assess the statistical significance of each covariate (Wooldridge, 2008).  
Aims 2a and 2b used Cox proportional hazard models (Cleves, Gould, 
Gutierrez, & Marchenko, 2010; D.W. Hosmer & Lemeshow, 1999). Each model was 
examined for the most appropriate variable functional forms, interaction terms, and 
higher-order terms as previously discussed. The Kaplan-Meier method (Cleves et 
al., 2010; D.W. Hosmer & Lemeshow, 1999) was used to plot time to event curves 
for patients of each race and to test each independent variable of interest for the 
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proportional hazards assumption. The logrank test was used to examine consistent 
differences between survival curves, by race, using a 5% level of significance. 
Aims 3a and 3b were examined using the EPRP lung cancer data. The 
analyses employed for Aim 3 mirror those described in Aim 2. All analyses were 
performed using Stata version 10.0 (Stata Corporation, College Station, Texas) and 
SAS version 9.2 (SAS Institute, Inc., Cary, North Carolina). 
 CHAPTER 4: EXAMINING POTENTIAL COLORECTAL CANCER CARE 
DISPARITIES IN THE VETERANS AFFAIRS HEALTHCARE SYSTEM  
 
 
OVERVIEW 
Racial disparities in cancer treatment and outcomes are a national problem. 
The nationwide Veterans Affairs (VA) health system seeks to provide equal access 
to quality care. However, the relationship between race and care quality for veterans 
with colorectal cancer (CRC) treated within the VA is poorly understood. We 
examined the association between race and receipt of NCCN guideline-concordant 
CRC care. 
This was an observational, retrospective medical record abstraction of CRC 
patients treated in the VA. Subjects included 2,022 patients (n=1,712, Caucasian; 
n=310, African American) diagnosed with incident CRC between October 1, 2003, 
and March 31, 2006, from 128 VA medical centers. We used multivariable logistic 
regression to examine associations between race and receipt of guideline-
concordant care (computed tomography scan, preoperative carcinoembryonic 
antigen, clear surgical margins, medical oncology referral for Stages II-III, 
fluorouracil-based adjuvant chemotherapy for Stage III, surveillance colonoscopy for 
Stages I-III). Explanatory variables included demographic and disease 
characteristics.  
There were no significant racial differences for receipt of guideline-concordant 
CRC care. Older age at diagnosis was associated with reduced odds of medical 
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oncology referral and surveillance colonoscopy. Presence of cardiovascular 
comorbid conditions was marginally associated with reduced odds of medical 
oncology referral (OR 0.65, 95% CI 0.50-0.89).  
In these data, we observed no evidence of racial disparities in CRC care 
quality, suggesting that the VA may be a leader in providing equitable CRC care. 
Future studies could examine causal pathways for the VA’s equal, quality care and 
ways to translate the VA’s success into other hospital systems.  
Introduction 
The Veterans Affairs (VA) healthcare system is the largest provider of 
integrated cancer care in the United States, treating approximately 3% of newly 
diagnosed cancer cases nationwide (Zullig et al., 2012). Colorectal cancer (CRC) is 
responsible for a substantial amount of cancer-related morbidity and mortality. It is 
the third most commonly diagnosed cancer and third most common cause of cancer-
related death for both men and women nationwide (Siegel et al., 2012). 
Racial differences in CRC screening, diagnosis, treatment, and mortality have 
been widely documented in non-federal U.S. healthcare systems (Benarroch-
Gampel et al., 2012; Berry et al., 2009; Berry et al., 2010; Crawford, Jones, & 
Richardson, 2010; Dimou, Syrigos, & Saif, 2009; Du et al., 2011; Kim et al., 2011; 
Obeidat et al., 2010; Rhoads, Cullen, Ngo, & Wren, 2012; Singh, Williams, 
Siahpush, & Mulhollen, 2011; White, Vernon, Franzini, & Du, 2010). Fewer AAs 
receive adjuvant chemotherapy for CRC compared to Caucasians (Dimou et al., 
2009; Jessup, Stewart, Greene, & Minsky, 2005; Obeidat et al., 2010). Compared to 
Caucasian patients, cancer surveillance is lower and cancer-related mortality is 
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higher among African American patients (Dimou et al., 2009; Singh et al., 2011; 
White et al., 2010). It has been hypothesized that a key reason for such disparities 
has been unequal access to healthcare services (Benarroch-Gampel et al., 2012; 
Laiyemo et al., 2010; Landrum, Keating, Lamont, Bozeman, & McNeil, 2012). 
Standard eligibility criteria and relatively narrow distribution of family income among 
VA patients make differences in access among individuals of different races 
narrower than for non-VA systems (Agha et al., 2000). Although racial disparities in 
care have been noted for some conditions or procedures, the degree of racial 
disparities in the overall quality of VA care is thought to be less than for other U.S. 
healthcare systems (Rabeneck et al., 2003; Robinson et al., 2010). 
There is paucity of information examining racial disparities in the quality of 
CRC care for VA patients of diverse race. Previous studies that have found some 
evidence that racial difference in CRC treatment may be attenuated in the VA 
(Alexander et al., 2007; Dominitz et al., 1998; Landrum, Keating, Lamont, Bozeman, 
& McNeil, 2012). However, these studies were based on a limited number of quality 
measures that could be assessed using administrative data alone. Thus, we extend 
previous research by using more comprehensive review of electronic health record 
data, supplemented with administrative data, to examine racial differences for 
receipt of guideline-concordant CRC care across the CRC care continuum. 
Methods 
Data Sources 
We obtained data from the VA EPRP, the national program for tracking 
quality of VA healthcare (Kussman, 2008). Between July and August 2007, medical 
 58 
record abstraction was conducted under the guidance of the VA Office of Quality 
and Performance to assess the quality of CRC care. Abstractors accessed the 
electronic health record remotely to collect data on disease characteristics and 
healthcare delivery provided to individuals across the VA nationwide. We 
supplemented EPRP data with clinical comorbidity and demographic information 
from the VACCR and administrative data (specifically inpatient and outpatient 
Medical SAS files).  
Patient Sample 
The sample has previously been described in detail (Jackson, Melton, et al., 
2010). Briefly, patients were identified for inclusion in EPRP based on a search 
algorithm that defined a representative sample of VA patients diagnosed with CRC 
between October 1, 2003, and March 31, 2006, using administrative diagnosis, 
procedure, and encounter data stored in the centralized VA Decision Support 
System (Hynes et al., 2004; Jackson, Melton, et al., 2010). Eligible patients had an 
ICD code for colon and/or rectal cancer within three months (prior to or after) the 
study diagnosis time period (AHRQ, 2012; Jackson, Melton, et al., 2010). Further, 
eligible patients must have had a clinic visit, surgical procedure, or pathology report 
in the VA that corresponded with a specific visit or receipt of medical services within 
the aforementioned time frame. These combinations of services could have occurred 
in any temporal order. To be in the final analytic data set, patients also must have: 
had non-metastatic CRC (Stages I to III), had an incident occurrence (first diagnosis 
of CRC occurred during the study time period), received definitive surgical resection 
for CRC, and have successfully linked with information from VA administrative data 
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sources. Because of the small number of non-African American minorities and 
females, we restricted the study to Caucasian and African American male patients 
(Figure 5). 
 
 
  
Figure 5. Colorectal cancer cohort assembly. 
 
Dependent Variables: Quality Indicators 
We used six distinct CRC quality indicators based on the 2003 NCCN 
guidelines (National Comprehensive Cancer Network, 2003a, 2003b) that have 
scientific evidence and/or NCCN panel consensus (Jackson, Melton, et al., 2010;  
National Comprehensive Cancer Network, 2003a, 2003b). Each indicator applied to 
a subset of patients as determined by stage and other factors. The specific quality 
indicators, by stage, were: 
 Stage II and Stage III CRC: (1) preoperative computed tomography (CT) 
scan of the abdomen and pelvis prior to definitive surgical resection; (2) 
preoperative carcinoembryonic antigen (CEA) determination prior to 
definitive surgical resection; (3) documented radial margins free of tumor 
at the time of definitive surgical resection; and (4) referral to a medical 
2,896 patients  
included in EPRP 
2,022 patients  
available for 
analysis 
874 patients excluded: 
 n=119 non-invasive/Stage 0 
 n=285 metastatic/Stage IV 
 n=8 missing comorbidity information 
 n=11 missing age at diagnosis 
 n=35 missing marital status 
 n=314 missing race 
 n=59 other minority race 
 n=43 women
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oncologist. Because our intent was to evaluate equity in access to quality 
care, patients with documentation of a refusal (e.g., refused CT scan) in 
the electronic medical record were included in the quality indicator as 
having received guideline-concordant care.  
 Stage III CRC: receipt of adjuvant fluorouracil- (5-FU) or capecitabine-
based chemotherapy administered after definitive surgical resection. If the 
medical record contained a documented reason that 5-FU was not 
administered, that was included in the quality indicator calculation as 
having received guideline-concordant care.  
 Stages I-III CRC who did not have documentation of an obstructing 
preoperative lesion: receipt of surveillance colonoscopy within seven to 
eighteen months after definitive surgical resection. Consistent with 
previous analyses (Jackson, Melton, et al., 2010), seven months was used 
as a minimum because colonoscopies performed earlier might not be 
intended for surveillance, and eighteen months was chosen because 
surveillance colonoscopies may not occur exactly within one year (e.g., 
due to scheduling or patient preference). To be included in the 
surveillance colonoscopy measure, patients must have survived at least 
one-year post-surgical resection. 
  
Independent Variables 
The primary independent variable of interest was patient race. We used a 
hierarchy of data sources to determine the most accurate measure of race. Because 
data were obtained through health record review by trained cancer registrars, the 
VACCR was considered the most valid source of race information and was available 
for most patients. If race was not reported in VACCR, then race was extracted from 
the inpatient medical record. If race was still unknown, then outpatient medical 
record information was used.  
Other covariates included marital status (married or not), age at diagnosis 
(less than 55 years, 55 to 64 years, 65 to 74 years, or 75 years or older), geographic 
region (west, south, east, or central), comorbid conditions, and, when applicable, 
stage of disease (I, II, or III). The included comorbid conditions were based on the 
NCI Combined Comorbidity Index, which has been validated with CRC patients 
 61 
(Klabunde et al., 2007). We identified diagnoses for comorbid conditions with ICD 
codes from medical inpatient and outpatient administrative data files (AHRQ, 2012). 
To be included, comorbid conditions must have been diagnosed within the year prior 
to the CRC diagnosis, excluding those comorbidities occurring in the thirty days 
leading up to diagnosis (e.g., diagnosis-365 days to diagnosis-30 days). This is 
because the thirty days prior to a cancer diagnosis often involve multiple interactions 
with the healthcare system and patients may be diagnosed, sometimes erroneously, 
with comorbidities that are actually cancer symptoms or sequelae. To ensure that 
our analysis had adequate statistical power to address our study question, we 
aggregated conditions based on consultation with a medical oncologist and 
statistical examination to ensure that no valuable information was lost (e.g., by 
collapsing a positively correlated condition with a negatively correlated condition) 
(Carpenter et al., 2012). Individual comorbid conditions included: 1) liver disease; (2) 
rheumatoid disease or AIDS; (3) renal disease; (4) dementia or paralysis; (5) 
congestive heart failure, acute myocardial infarction, cardiovascular disease, or 
chronic obstructive pulmonary disease; and (6) diabetes. This approach enabled us 
to examine the effect of specific conditions on receipt of guideline-concordant care, 
an advantage over an aggregate comorbidity index score.  
Data Analysis 
Multivariable logistic regression was used to determine the association 
between race and receipt of guideline-concordant CRC care. To determine the best-
specified model, Likelihood Ratio (LR) tests were conducted and pseudo R-squared 
variables were compared. Pearson’s chi-square tests were used to determine 
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whether there were significant differences between groups for background 
demographic and clinical characteristics (e.g., age groups). Pearson and phi 
correlations between variables were assessed to examine potential for 
multicollinearity. We report odds ratios (OR) and 95% confidence intervals (CI). This 
paper examines multiple comparisons among the independent variables (e.g., race, 
age at diagnosis), which may increase the likelihood of Type 1 error (e.g., rejecting 
the null hypothesis when it is true). As a result, we considered using either the Šidák 
or Bonferroni correction. The Šidák correction relies on the assumption that the tests 
are independent. This claim is questionable in the current context. Sensitivity 
analyses using the Šidák (Sidak, 1967) and Bonferroni (Miller, 1981) corrections 
yielded results that were essentially identical and yielded no difference in 
interpretation of results. Therefore, we used the Bonferroni multiple comparison 
correction to control for family-wise error (i.e. the probability of making a false 
discovery). As a result of this correction, we only consider an association between 
independent variables and a specific quality indicator to be statistically significant if 
the p-value is <0.01 as opposed to the conventional value of <0.05. Stata 11 
(StataCorp LP, College Station, TX) and SAS version 9.2 (SAS Institute, Cary, NC) 
were used for data management and analyses. 
Results 
The final sample consisted of 2,022 men with incident CRC (Figure 5). The 
mean age at diagnosis was 68 years (range: 34—94 years). Reflecting the overall 
VA patient population, the sample was predominately Caucasian (85%), married 
(52%), and lived in the South (38%). Stage was approximately evenly distributed. 
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The most commonly diagnosed comorbid conditions were diabetes (27%) and 
cardiovascular-related diseases (24%). Few patients were affected by other 
comorbid conditions (Table 7). The correlation matrix between independent 
variables suggested that there was no unanticipated impact of multicollinearity 
(results not shown).  
There were no significant racial differences in receipt of quality CRC care in 
the VA (Table 8 and Table 9). In these data, race was not associated with receipt of 
guideline concordant care for the examined quality indicators. 
Compared to patients 75 years or older at diagnosis, patients aged 55—64 
years at diagnosis had marginally greater odds of having a preoperative CT scan 
(OR 1.51, 95% CI 1.11-2.05). Similarly, compared to patients age 75 years or older, 
younger patients had greater odds of a medical oncology referral (under 55 years, 
OR 2.45, 95% CI 1.42-4.23; 55 years to 64 years, OR 1.89, 95% 1.34-2.65; 65 years 
to 74 years, OR 1.66, 95% CI 1.18-2.35) (Table 8). Patients who were 65 years to 
74 years old had greater odds of receiving surveillance colonoscopy than patients 
who were 75 years or older (OR 1.47, 95% CI 1.14-1.89) (Table 9). For the 
remaining quality measures there were no associations between age at diagnosis 
and receipt of guideline-concordant care. 
For the majority of quality indicators, there was no association between 
presence of an individual comorbid condition and receipt of guideline-concordant 
care. Patients with cardiovascular-related comorbidities had marginally lower odds of 
referral to a medical oncologist (OR 0.65, 95% CI 0.50-0.89) than patients without 
cardiovascular conditions (Table 8).  
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Limited associations between stage and receipt of guideline-concordant care 
may be reflective of severity of disease. Patients with Stage III disease had lower 
odds of having clear surgical margins (OR 0.44, 95% CI 0.31-0.62) than those with 
Stage II disease (Table 8). Additionally, patients with Stage III disease had 
increased odds of referral to medical oncology (OR 2.70, 95% CI 2.03-3.60) 
compared to those with Stage II disease (Table 8). Odds of receiving surveillance 
colonoscopy were lower among patients with Stage I disease (OR 0.71, 95% CI 
0.56-0.90) compared to Stage II (Table 9). 
DISCUSSION 
Prior to 1995, VA care was criticized for its overall organization and 
management and providing poor quality of care. Gardner, 1998; Perlin, 2006). In 
1995 the VA began a system-wide transformational redesign with emphasis on using 
information technology, measuring and reporting quality performance, and 
integrating services across medical specialties (Anderson, 2005; Eisen & Francis, 
2010; Jackson & Weinberger, 2009; Jha et al., 2003). More recent reports suggest 
that the VA is now a leader in information technology and the delivery of high-quality 
care (Asch et al., 2004; Jackson, Melton, et al., 2010; Jha et al., 2003; Keating et al., 
2011). The question that we address is whether this transformation in overall quality 
also reduced racial disparities in the guideline-concordant CRC care.  
We found a lack of evidence of racial disparities in receipt of guideline-
concordant CRC care. The lack of evidence of racial disparity contrasts with 
numerous prior studies in non-federal hospitals that observed racial differences in 
receipt of CRC care, for example, in receipt of screening colonoscopies (Benarroch-
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Gampel et al., 2012; Rich, Kuyateh, Dwyer, Groves, & Steinberger, 2011; White, 
Vernon, Franzini, & Du, 2011). However, there is a dearth of information about racial 
differences in receipt of surveillance colonoscopy following surgical resection. Our 
study found no racial differences for surveillance colonoscopy.  
Colonoscopy is not without risks; differences in receipt of surveillance 
colonoscopy based on stage and age at diagnosis may be appropriate. There is 
evidence that intensive post-surgery surveillance can increase survival (Figueredo et 
al., 2003; Jeffery, Hickey, & Hider, 2002; Renehan, Egger, Saunders, & O'Dwyer, 
2002), but a direct clinical benefit for surveillance colonoscopy alone has not been 
established. Despite this, clinical guidelines assert that surveillance colonoscopy is 
an important component of guideline-concordant surveillance for CRC patients 
(Desch et al., 2005; National Comprehensive Cancer Network, 2003a, 2003b).  
Studies from the Surveillance Epidemiology and End Results-Medicare 
registry found differences in oncologist evaluation rates between Caucasian and 
African American patients, but the gap decreased substantially over time. Moreover, 
contingent on consulting with a medical oncologist, there were no racial differences 
in receipt of treatment (Davidoff et al., 2009). However, there are differences based 
on age at diagnosis. Clinical trials generally do not enroll elderly people. As a result, 
the clinical benefit of adjuvant chemotherapy on older people has not been tested 
extensively in a trial setting and older patients often do not receive 5-FU–based 
chemotherapy in the private healthcare setting (Ades, 2009). Regarding race, there 
is evidence that the clinical benefit of 5-FU may be lower for African American 
patients than for Caucasian patients (Jessup et al., 2005; Yothers et al., 2011).  
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In our analysis, age and stage at diagnosis were associated with referral to a 
medical oncologist. The difference in stage, where patients with Stage III disease 
have greater odds of referral than patients with Stage II disease, is likely clinically 
appropriate. Our study sample was diagnosed in 2003—2006. At the time that these 
patients received treatment, chemotherapy for patients with Stage II disease was 
somewhat controversial. This association may reflect clinicians’ knowledge of clinical 
practice guidelines. However, differences in referral patterns based on stage, age, 
and specific cancer type (e.g., colon, rectal) need to be examined further. We found 
no association between race and referral to medical oncology. Referral to a medical 
oncologist typically precedes receipt of chemotherapy. In this VA population, we also 
found no association between race or age and receipt of 5-FU—based 
chemotherapy. 
We found differences in receipt of care based on the presence of specific 
comorbid conditions, specifically; patients with cardiovascular conditions were less 
likely to be referred to a medical oncologist. This may be related to contraindications 
for chemotherapy use in those with cardiovascular conditions. The clinical 
appropriateness of this was not addressed in our study.  
There are several limitations to this study. First, we were unable to control for 
potentially confounding socio-demographic status (e.g., annual household income, 
level of education), which may affect the relationship between race and quality of 
care. This potential omission bias is likely mitigated because VA patients receive 
care on a sliding fee scale based on their ability to pay, as evaluated by a financial 
needs assessment, and by their service-connected status (e.g., any physical or 
 67 
mental military service—related injuries, illnesses, or traumas) (Veterans Affairs, 
2011). Nearly one-half of VA patients have family incomes of less than $20,000 
(Agha et al., 2000). Second, we did not have information regarding Hispanic 
ethnicity. Third, data were abstracted from VA electronic medical record and 
administrative data; we lacked data on care outside of the VA healthcare system or 
care not documented in the available data sources. Our results are based on a 
modest sample size. Moreover, although we examined the potential associations 
between race and receipt of quality VA CRC cancer, we could not address possible 
reasons for the VA’s lack of disparities. The VA strives to be an equal-access 
system, which may be one reason for the success in this area. Other reports have 
hypothesized that this is a potential reason for reduced levels of healthcare 
disparities in the VA (Dominitz et al., 1998; Jackson, Powell, et al., 2010; Page & 
Kuntz, 1980). Generalizability of findings has been questioned in studies of VA 
populations; however, it is notable that our sample population is of similar age (e.g., 
68 years in our sample, 69 nationally) and stage distribution to that of the United 
States male colon cancer population.  
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Table 7. 
 
Description of CRC Patient Cohort and Key Variables. (n=2,022) 
 n Percent
Dependent variables   
CT scan 1022 72.48
Preoperative CEA 1175 83.33
Clear surgical margins 1155 87.83
Referral to a medical oncologist 1103 78.23
Adjuvant 5-FU chemotherapy 487 74.58
Surveillance colonoscopy 2022 43.31
Independent variable  
Caucasian race 1712 84.67
Other control variables  
Age at Diagnosis  
<55 years  180 8.90
55-64 years  615 30.42
65-74 years  576 28.49
75+ years 651 32.20
Married 1045 51.68
Region  
South 760 37.59
North 386 19.09
Central  451 22.30
West 425 21.02
Stage at Diagnosis  
Stage I 612 30.27
Stage II 757 37.44
Stage III 653 32.29
Individual Comorbid Conditions  
Liver disease 11 0.54
Rheumatoid disease or AIDS 23 1.14
Renal disease 53 2.62
Dementia or paralysis 5 0.25
CHF, acute MI, CVD, or COPD 485 23.99
Diabetes 541 26.76
 
 
In summary, we observed no evidence of racial disparities in receipt of quality 
CRC care provided by the VA healthcare system. As other clinical programs within 
the VA seek to strengthen or refine their approach to quality management and 
improvement, they may evaluate the lessons that can be learned from successful 
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colorectal cancer programs and specific changes such as electronic reminder 
systems, multidisciplinary collaborative improvement groups, and electronic tools for 
quality monitoring. Given that the VA treats 3% of newly diagnosed cancers annually 
(Zullig et al., 2012) it is plausible that the benefit of widespread quality improvement 
within the VA would influence the landscape of cancer care and outcomes nationally. 
Moreover, other healthcare systems could also consider aspects of VA care that 
could be translatable to reduce racial disparities in cancer care. Future studies with 
larger sample sizes are needed to examine causal pathways for the VA’s equal, 
quality care and ways to translate the VA’s success into other hospital systems.  
 
 TABLE 8. 
 
Multivariable logistic regression results for measures involving Stage II and III CRC patients. 
 Preoperative CT Scan Preoperative CEA Clear Surgical Margins Referral to Medical Oncologist
 OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p 
     
Demographic Characteristics           
Caucasian  1.22 0.88-1.70 0.23† 1.17 0.80-1.72 0.41* 0.71 0.43-1.19 0.19* 1.46 1.00-2.13 0.05* 
Married 0.82 0.64-1.04 0.11† 1.13 0.84-1.50 0.42* 1.02 0.73-1.44 0.90* 0.85 0.64-1.11 0.23* 
Age at Diagnosis            
<55 years  1.03 0.67-1.58 0.88* 1.04 0.62-1.80 0.87* 0.70 0.39-1.25 0.23* 2.45 1.42-4.23 <0.01* 
55-64 years 1.51 1.11-2.05 0.01* 1.33 0.91-1.93 0.14* 0.90 0.58-1.38 0.62* 1.89 1.34-2.65 <0.01* 
65-74 years 1.20 0.59-1.63 0.24* 0.87 0.61-1.24 0.44* 1.00 0.63-1.60 1.00* 1.66 1.18-2.35 <0.01* 
75+ years (referent)            
Region             
North 1.71 1.20-2.43 <0.01* 1.32 0.88-1.98 0.18* 2.25 1.22-4.14 0.01* 3.22 1.96-5.30 <0.01* 
Central  1.91 1.37-2.67 <0.01* 0.98 0.69-1.41 0.93* 0.93 0.60-1.43 0.73* 1.25 0.86-1.82 0.23* 
West 1.21 0.88-1.66 0.24* 2.88 1.79-4.64 <0.01* 0.85 0.55-1.31 0.46* 0.42 0.30-0.58 <0.01* 
South (referent)            
Comorbid Conditions           
Liver disease 1.15 0.23-5.82 0.86* 0.37 0.08-1.61 0.18* 0.47 0.09-2.48 0.38* 0.78 0.14-4.34 0.78* 
Rheumatoid 
disease or 
AIDS 
0.99 0.34-2.91 0.99* 0.63 0.20-1.99 0.43* -- -- -- 1.53 0.42-5.59 0.52* 
Renal 
disease 
0.60 0.30-1.24 0.17* 3.43 0.80-14.65 0.10* 1.80 0.41-7.85 0.43* 1.08 0.46-2.54 0.85* 
Dementia or 
paralysis 
0.67 0.11-4.20 0.67* 0.13 0.02-0.83 0.03* 0.18 0.03-1.15 0.07* 1.27 0.13-12.15 0.84* 
CHF, acute 
MI, CVD, or 
COPD 
0.82 0.63-1.09 0.19* 0.96 0.69-1.35 0.82* 0.86 0.58-1.29 0.47* 0.65 0.50-0.89 0.01* 
Diabetes 0.93 0.71-1.23 0.62* 1.03 0.73-1.43 0.88* 1.20 0.80-1.80 0.38* 1.02 0.74-1.40 0.90* 
Stage at Diagnosis            
Stage III 1.06 0.83-1.35 0.63* 1.04 0.78-1.38 0.81* 0.44 0.31-0.62 <0.01* 2.70 2.03-3.60 <0.01* 
Stage II (referent)            
             
N 1410   1410   1393   1410   
--Due to perfect prediction between the Rheumatoid disease or AIDS variable and the dependent variable, 17 observations were dropped from the 
regression model. 
*Indicates statistical significance at the <0.01 alpha level. We utilized the Bonferroni adjustment for multiple comparisons of independent variables, 
controlling for familywise error (e.g., Type I error, the probability of making a false discovery). 
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Table 9. 
 
Multivariate Logistic Regression Results for Receipt of Adjuvant 5-FU–based 
Chemotherapy and Surveillance Colonoscopy. 
Adjuvant 5-FU Chemotherapy† Surveillance Colonoscopy 
 OR 95% CI p  OR 95% CI p 
    
Demographic Characteristics Demographic Characteristics 
Caucasian race 1.23 0.77-1.97 0.40† Caucasian race 1.32 1.01-1.73 0.04*
Married 1.30 0.90-1.88 0.16† Married 1.00 0.82-1.22 1.00*
Age at Diagnosis Age at Diagnosis
<55 years  1.70 0.86-3.38 0.13† <55 years  1.12 0.77-1.62 0.55*
55-64 years  1.03 0.65-1.62 0.91† 55-64 years  1.20 0.93-1.53 0.16*
65-74 years  1.15 0.71-1.87 0.57† 65-74 years  1.47 1.14-1.89 <0.01*
75+ years (referent) 75+ years (referent) 
Region  Region  
North 1.75 1.00-3.07 0.05* North 1.28 0.96-1.71 0.09*
Central  1.52 0.95-2.42 0.08* Central  0.84 0.65-1.08 0.18*
West 1.30 0.79-2.14 0.31* West 1.01 0.77-1.33 0.93*
South (referent) South (referent) 
Comorbid Conditions Comorbid Conditions 
Liver disease 0.28 0.04-2.11 0.22* Liver disease -- -- -- 
Rheumatoid 
disease or AIDS 
1.11 0.20-6.17 0.90* Rheumatoid 
disease or AIDS 
1.00 0.40-2.46 0.99*
Renal disease 0.68 0.22-2.14 0.51* Renal disease 0.87 0.49-1.56 0.65*
Dementia or 
paralysis 
0.17 0.01-2.03 0.16* Dementia or 
paralysis 
-- -- -- 
CHF, acute MI, 
CVD, or COPD 
0.82 0.53-1.25 0.35*  CHF, acute MI, 
CVD, or COPD 
0.84 0.67-1.06 0.14*
Diabetes 0.84 0.56-1.26 0.40* Diabetes 0.86 0.69-1.08 0.20*
  Stage at Diagnosis
  Stage I 0.71 0.56-0.90 <0.01*
  Stage II (referent) 
  Stage III 0.97 0.77-1.24 0.83*
    
N 653 N 2006 
†Stage is not included as a covariate in the regression model examining adjuvant 5-FU–based 
chemotherapy. This is because only patients with Stage III CRC were included per NCCN guidelines. 
--Due to perfect prediction between liver disease and the dependent variable, 11 observations were 
dropped from the regression model; due to perfect prediction with dementia or paralysis, 5 
observations were dropped. 
*Indicates statistical significance at the <0.01 alpha level. We used the Bonferroni adjustment for 
multiple comparisons of independent variables, controlling for family-wise error (e.g., Type I error, the 
probability of making a false discovery). 
 
 CHAPTER 5: RELATIONSHIP BETWEEN RACE AND TIMELINESS OF 
COLORECTAL CANCER CARE IN THE VETERANS AFFAIRS HEALTHCARE 
SYSTEM 
 
OVERVIEW 
Veterans Affairs (VA) manages the largest United States integrated 
healthcare system. Although quality of VA colorectal cancer (CRC) care is well 
chronicled, there is a paucity of research examining racial differences in VA CRC 
care. This study examines racial differences in two dimensions of quality of VA CRC 
care: processes (time to treatment) and outcomes (survival). 
Retrospective data were from the VA EPRP, a nationwide VA quality-
monitoring program. Study patients were Caucasian and African American men 
diagnosed with non-metastatic CRC between 2003 and 2006 and received definitive 
CRC surgery. We examined three quality indicators—time from: 1) surgery to 
initiation of adjuvant chemotherapy (Stage II-III); 2) surgery to surveillance 
colonoscopy (Stage I-III); and 3) surgery to death (Stage I-III). Unadjusted analyses 
used Log-rank and Wilcoxon tests. Adjusted analyses used Cox proportional hazard 
models. 
In unadjusted analyses, there was no evidence of racial differences across 
the three quality measures. In adjusted Cox regression there were no racial 
differences in time to initiation of chemotherapy (HR 0.82, p=0.61) or surgery to 
death (HR 0.94, p=0.49). In adjusted Cox regression, Caucasian patients 
experienced slightly shorter median times to surveillance colonoscopy than African 
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American patients (367 versus 383 days, HR 0.63, p=0.02). Other than a small racial 
difference in timing of surveillance colonoscopy, there was little evidence of racial 
differences in quality of CRC care among VA healthcare system users.  
INTRODUCTION 
The Department of Veterans Affairs (VA) manages the largest integrated 
healthcare system in the United States, treating approximately 3% of patients with 
cancer (Zullig et al., 2012). Since its national reorganization and transformation in 
the mid-1990s (Kizer & Dudley, 2009), the VA has been a leader in providing high-
quality, equitable care. The quality of cancer care provided in the VA has been 
extensively examined, with the VA generally performing equal to or better than the 
private sector (Keating et al., 2011; Landrum, Keating, Lamont, Bozeman, Krasnow, 
et al., 2012). Quality of colorectal cancer (CRC) care in particular has been lauded 
as an area in which the VA provides excellent care (Keating et al., 2011; Landrum, 
Keating, Lamont, Bozeman, Krasnow, et al., 2012). In addition to providing quality 
care overall, there is evidence that racial disparities in CRC care quality may be less 
significant in the VA compared with non-federal healthcare systems (Alexander et 
al., 2007; Dominitz et al., 1998; Landrum, Keating, Lamont, Bozeman, & McNeil, 
2012). 
An important process measure reflecting quality care is timeliness in receiving 
evidence-based treatments. The VA has longstanding processes for quality 
monitoring and performance improvement, focused on achieving guideline-
concordant clinical care, which may support its success as a leader in provision of 
quality care (Francis & Perlin, 2006; McQueen et al., 2004; Trivedi & Grebla, 2011; 
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Trivedi et al., 2011). There is a system-wide emphasis on adhering to guidelines 
based on strong scientific and clinical evidence. However, standards for timeliness 
of care are largely consensus-based. Perhaps as a result, timeliness standards have 
not been widely implemented in the VA or other large, integrated healthcare 
systems. The VA has evaluated several CRC interventions and collaborative efforts 
to address delays in diagnosis and follow-up on positive screening tests (Fisher et 
al., 2010; Partin, Powell, Nugent, & Ordin, 2011; Powell, Gravely, Ordin, Schlosser, 
& Partin, 2009). Less attention has been focused on timeliness of care during CRC 
treatment and early surveillance phases.  
Survival can be considered an outcome measure of quality. Although several 
studies examining survival have produced mixed results about the presence of racial 
differences (Dominitz, Maynard, Billingsley, & Boyko, 2002; Dominitz et al., 1998; 
Robinson et al., 2010), there is a paucity of literature describing racial differences in 
timeliness of VA CRC care. Landrum and colleagues compared cancer-specific and 
all-cause mortality rates for men older than 65 years receiving care in the VA versus 
fee-for-service Medicare. Compared with similar fee-for-service Medicare patients, 
survival rates for VA users with CRC were equal or better (Landrum, Keating, 
Lamont, Bozeman, Krasnow, et al., 2012). In the 1990s, Dominitz and colleagues 
examined potential racial differences in CRC survival rates, finding similar relative 
five-year survival rates for African American and Caucasian CRC patients seeking 
care in the VA healthcare system (Dominitz et al., 1998). Jackson and colleagues 
examined the timeliness of treatment for non-metastatic CRC patients in the VA 
healthcare system. For patients with Stage II and III disease, they found a median of 
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twenty days between diagnosis and initiation of CRC treatment. There was a median 
of fifty days between definitive surgical resection and start of adjuvant chemotherapy 
(Jackson, Melton, et al., 2010). The authors did not examine patient or disease 
characteristics associated with timeliness of care.  
We expand previous work by examining racial differences in two dimensions 
of quality of VA CRC care: processes (time to treatment) and outcomes (survival). 
METHODS 
Data Source and Patient Sample 
The VA EPRP, the national program for assessing quality of VA healthcare, 
was the primary data source (Kussman, 2008). In 2007, the VA Office of Quality and 
Performance oversaw a national medical record abstraction effort to assess the 
quality of CRC care. Abstractors accessed the electronic health record remotely, 
collecting data on disease characteristics and healthcare delivery provided to 
patients throughout the VA healthcare system. We augmented EPRP data with 
clinical comorbidity and demographic information contained in the VACCR and 
administrative data (specifically inpatient and outpatient Medical SAS files).  
The sample has previously been described in detail (Jackson, Melton, et al., 
2010). Succinctly, patients were identified for inclusion in EPRP based on a search 
algorithm that defined a representative sample of VA patients diagnosed with CRC 
between October 1, 2003, and March 31, 2006. The algorithm made use of 
administrative diagnosis, procedure, and encounter data stored in the centralized VA 
Decision Support System (Hynes et al., 2004; Jackson, Melton, et al., 2010). Eligible 
patients had an ICD-9 code for colon and/or rectal cancer within three months 
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(before or after) the study diagnosis time period (AHRQ, 2012). Eligible patients 
must also have had a clinic visit, surgical procedure, or pathology report in the VA 
that corresponded to receipt of medical services within the aforementioned 
timeframe. The final analytic data set included patients with: non-metastatic CRC 
(Stages I to III); an incident occurrence (first diagnosis of CRC occurred during the 
study time period); receipt of definitive surgical resection for CRC; and a successful 
link with information from VA administrative data sources. Because of the small 
number of non-African American minorities and females, analyses were restricted to 
Caucasian and African American male patients (Figure 5). We did not have 
information regarding Hispanic ethnicity.  
Measures 
We examined three stage-specific quality metrics for CRC care: 1) time from 
definitive CRC surgical resection to initiation of 5-FU-based adjuvant (e.g., post-
operative) chemotherapy (Stage II or III) (Biagi et al., 2011), 2) time from definitive 
surgical resection to receipt of surveillance colonoscopy (Stage I, II, or III) (Desch et 
al., 2005; Figueredo et al., 2003;  National Comprehensive Cancer Network, 2003a, 
2003b; Salz, Woo, Starr, Jandorf, & Duhamel, 2012; Winawer et al., 2003), and 3) 
time from definitive CRC surgical resection to death (Stage I, II, or III). The first two 
measures reflect process indicators of quality while the third indicator measures 
survival as a critical outcome. We also examined whether comorbidities and 
demographic factors were mediators of differences in survival and other timeliness 
of care events. 
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The date of surgical resection was used as the anchor date for all three 
measures for several reasons. First, the date of surgery is a decisive date, unlike the 
date of diagnosis, which is often difficult to define (e.g., date of positive screening 
test, date of pathology report, date of physician’s suspicion of CRC, etc.). 
Exploratory analysis of these data confirmed that for many patients the date of 
surgery preceded the date of diagnosis, likely due to ambiguity about the date of 
diagnosis. Second, all patients in the sample underwent surgical resection, making it 
a feasible anchor date. Finally, some patients may have been diagnosed outside of 
the VA healthcare system but then entered the VA healthcare system for their 
cancer care. Using the surgery date as the index enables a better examination of 
processes of care within the VA. 
Additional inclusion and exclusion criteria were applied for each of the three 
quality measures. For surveillance colonoscopy, patients must have survived at least 
one-year post-surgery to be included in analysis. Most clinical guidelines during this 
time period, including NCCN (National Comprehensive Cancer Network, 2003a, 
2003b) and the American Cancer Society (Rex et al., 2006), recommended a 
surveillance colonoscopy at one-year post-surgery. We limited surveillance 
colonoscopies to those occurring within seven to eighteen months post-surgery 
because colonoscopies occurring prior to seven months post-surgery might be 
diagnostic; the maximum of eighteen months reflects pragmatic challenges to 
receiving this test within the recommended twelve months (e.g., scheduling 
challenges, patient preference). For each of the three quality indicators, we 
calculated the number of days between the surgery date and the date of the event.  
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Covariates, identified a priori, included patient characteristics associated with 
timeliness of cancer care (Cooper, Kou, & Reynolds, 2008; Long et al., 2012; Salz et 
al., 2010). We considered both demographic (age at diagnosis, marital status, 
geographic region) and disease (stage at diagnosis, comorbidity) characteristics. 
The comorbidity measure was the NCI Combined Comorbidity score, created from 
inpatient and outpatient medical record data from one year prior to CRC diagnosis 
until one month prior to diagnosis. This weighted comorbidity score has previously 
been validated among a CRC cohort (Klabunde et al., 2007).  
Statistical Analysis 
Multicollinearity between the covariates was examined as part of a previous 
analysis and no collinearity was identified. We used the Kaplan-Meier method to 
estimate time-to-event curves. To compare differences in unadjusted survival 
curves, we used the Log-rank and Wilcoxon tests. Multivariate Cox proportional 
hazards models were employed to assess the prognostic power of race for time-to-
event in the presence of the aforementioned covariates. The Efron method was used 
to handle ties (Cleves et al., 2010; Kleinbaum, 1996). Data management and 
analyses were conducted in Stata 11 (StataCorp LP, College Station, TX) and SAS 
version 9.2 (SAS Institute, Cary, NC). 
RESULTS 
The final sample consisted of 2,022 men who met eligibility criteria (Figure 5). 
Reflecting the overall VA patient population, the sample had a mean age at 
diagnosis of 68 years. The majority of patients were Caucasian (85%), married 
(52%), and lived in the South (38%). Stage was approximately evenly distributed. 
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The mean NCI combined comorbidity index score was 0.27 (Table 10). The most 
commonly diagnosed individual comorbid conditions were diabetes (27%) and 
cardiovascular-related diseases (24%) (results not shown).  
Across the sample, the median time from surgery to initiation of adjuvant 5-
FU–based chemotherapy was forty-nine days; medians were not statistically 
different for African American and Caucasian patients (55 versus 49 days, 
respectively; p=0.71). In unadjusted analyses, there were no statistically significant 
racial differences in time-to-event curves for surgery to initiation of adjuvant 5-FU–
based chemotherapy (Wilcoxon p=0.78; Log-rank p=0.10). Similarly, in adjusted 
multivariable Cox regression, race was not associated with time from surgery to start 
of adjuvant 5-FU–based chemotherapy (HR=0.82, p=0.61). The region in which 
patients received care was significant. Compared to those living in the South, 
patients living in the North (HR=0.06, p=0.01) and Central (HR=0.33, p=0.04) 
regions had shorter times from surgery to chemotherapy. Small sample sizes did not 
permit us to explore race by region interactions.  
When examining colonoscopies occurring within seven to eighteen months 
following surgical resection, the median time from surgery to first surveillance 
colonoscopy was 367 days. Unadjusted analyses found no statically significant 
differences in medians between African American and Caucasian patients (374 
versus 367 days, p=0.10) or in time-to-event curves for time from surgery to first 
surveillance colonoscopy (Wilcoxon p=0.23; Log-rank p=0.05). In adjusted 
multivariable regression analyses, a racial difference in time to receipt of first 
surveillance colonoscopy was suggested. Caucasian race was protective for shorter 
 80 
time to surveillance colonoscopy (HR=0.63, p=0.02; Table 11). Though the 
association was statistically significant, the magnitude of the difference is small (16 
days) and not likely clinically meaningful. Compared to patients living in the South, 
those living in the Central region (HR=1.84, p=0.00) had longer times from surgery 
to colonoscopy. Compared to patients aged 75 or older, patients (HR=1.60, p=0.04) 
aged 65–74 years had slightly longer times to colonoscopy.  
Across the sample, the median time from surgery to death was 1,053 days, 
and the unadjusted difference was similar for African American and Caucasian 
patients (1,050 versus 1,062 days, respectively; p=0.04). In unadjusted analyses, 
there were no statistically significant racial differences in time-to-event curves in time 
from surgery to death (Wilcoxon p=0.32; Log-rank p=0.33).  
Similarly, in adjusted multivariable Cox regression, race was not associated 
with time from surgery to death (HR=0.94, p=0.49). Notably, several covariates were 
significant. Patients aged 55 years or younger had a lower hazard of death 
compared to patients 75 years or older (HR=0.76, p=0.04). Compared to patients 
with Stage II disease, those with Stage I disease had reduced hazards of death 
(HR=0.83, p=0.04) and those with Stage III disease had increased hazards of death 
(HR=1.32, p=0.00), which would be expected based on known clinical outcomes for 
cancer stage (Table 11). 
DISCUSSION 
We examined whether racial differences existed in the quality of CRC care 
delivered by the VA, the largest integrated health care system in the United States. 
Using two stage-specific, evidence-based process measures (time to adjuvant 
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chemotherapy and time to colonoscopy) and patient outcome (survival following 
surgery), we found no meaningful racial disparities with respect to these three quality 
measures. These findings support the perception of the VA as an “equal access 
system” committed to the provision of quality, timely CRC care (Kizer & Dudley, 
2009; Perlin et al., 2004; Robinson et al., 2010). 
The first process quality measure examined was time from surgery to 
initiation of 5-FU–based adjuvant chemotherapy. Consistent with previous literature, 
we found that the VA provides racially equal care on this metric (Dominitz et al., 
1998). We identified possible geographic variations in care. Due to the sample size, 
this analysis aggregated regional data at a relatively high level (e.g., four geographic 
regions nationwide). Based on these data, we do not know whether patients of 
different race who are receiving healthcare in the VA system disproportionately live 
in specific geographic regions. It is possible that these regional differences confound 
the ability to accurately assess racial differences. Future analyses could further 
investigate this phenomenon using more granular regional data.  
In our analyses, potential racial differences were only identified for one 
process measure—receipt of surveillance colonoscopy. The difference in elapsed 
time to colonoscopy between the two groups (approximately sixteen days on 
average) is small and the clinical significance of this difference is likely minimal. To 
ensure that this gap does not widen, additional research is needed to understand 
underlying mechanisms creating this time difference. Though not the focus of our 
analyses, there is nearly universal evidence that CRC survivors receive inadequate 
colonoscopic surveillance. The under-provision of surveillance colonoscopy has 
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been documented among Medicare users, population-based patient samples, and 
among users of the VA healthcare system (Cooper et al., 2008; Jackson, Melton, et 
al., 2010; Salz et al., 2010; Salz et al., 2012). Although surveillance colonoscopy is 
generally under-received, previous studies have suggested patients of Caucasian 
and African American race receive colonoscopy equitably within the VA healthcare 
system (Dominitz et al., 1998). This is important contextual information for 
interpreting our study findings. This finding is consistent with previous studies on the 
subject. A recent systematic literature review by Salz and colleagues examined 
differences in timeliness of colonoscopy use among CRC survivors receiving care at 
multiple types of healthcare institutions (Salz et al., 2012). The authors identified 
eight studies addressing racial differences in time to colonoscopy. Half of the articles 
described a small but significant racial difference in receipt of timely colonoscopy; 
the remaining half showed a non-significant trend in the same direction (Salz et al., 
2012). There is no scientific evidence suggesting that a narrow difference in time 
(e.g., sixteen days on average) would impact care quality or patient outcome. There 
were also differences in age at diagnosis and receipt of surveillance colonoscopy, 
where older people were less likely to receive a timely colonoscopy than their 
younger counterparts. This is as anticipated. Increasing age is often associated with 
decreased performance status and increased comorbidity burden. Therefore, it is 
possible that few patients aged 75 or older would be expected to receive 
surveillance colonoscopy and, for those that do receive surveillance colonoscopy, 
the timeline may be extended. 
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As an outcome of care quality, we examined post-surgical survival times and 
identified similar times among different racial groups. In non-federal healthcare 
settings, including integrated systems serving Medicare patients, there have been 
mixed findings regarding racial differences in CRC survival (Bradley et al., 2001; 
Dominitz et al., 1998; Pulte et al., 2012; Rabeneck et al., 2003). Our finding of 
similar post-surgical survival rates between Caucasian and African American 
patients may suggest that the VA provides similar processes of quality care to 
patients throughout their disease trajectory translating into comparable survival 
times. This hypothesis is supported by existing literature (Jackson, Melton, et al., 
2010; Rabeneck et al., 2003). 
This analysis has several limitations. First, veterans who receive care through 
the VA healthcare system have greater comorbidity than the general population 
(Agha et al., 2000). We adjusted for comorbidity, but some patients may have 
appropriately not received care (e.g., too frail to undergo colonoscopy). Our analysis 
was limited to care received in the VA. Some patients receiving care in the VA 
healthcare system may also receive a portion of their cancer care elsewhere. Future 
research should endeavor to include information from multiple data sources. 
Despite these limitations, our analysis provided important insight into the 
quality and timeliness of VA CRC care. We assessed key process and outcome 
measures of care quality and observed no evidence of clinically meaningful racial 
differences in timeliness of CRC care provided by the VA healthcare system. This 
may be a testament to the VA’s history as an “equal access system” (Kizer & 
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Dudley, 2009; Perlin et al., 2004; Robinson et al., 2010) and its established 
commitment to ongoing quality monitoring and improvement. 
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Table 10. 
 
Description of CRC Patient Cohort and Key Variables. 
  Caucasian 
Patients 
(n=1,712) 
African American  
Patients 
(n=310) 
Full  
Sample 
(n=2,022) 
 % (n) or  
Mean (SD) 
% (n) or  
Mean (SD) 
% (n) or  
Mean (SD) 
Dependent variables   
Days from surgery to adjuvant 5-
FU chemotherapy 
63.5 (55.1) 65.6 (45.6) 63.8 (53.6)
Days from surgery to surveillance 
colonoscopy 
375.9 (77.2) 376.4 (78.6) 376.0 (77.3)
Days from surgery to death 1,136.6 (730.4) 988.0 (1,258.6) 1,112.9 (838.1)
Independent variable  
 Caucasian race 100% (1,712) 0% (0) 84.7% (1,712)
Other control variables  
Age at Diagnosis  
<55 years  8.1% (138) 13.6% (42) 8.9% (180)
55-64 years  30.5% (522) 30.0% (93) 30.4% (615)
65-74 years  28.7% (492) 27.1% (84) 28.5% (576)
75+ years 32.7% (560) 29.4% (91) 32.2% (651)
Married 53.9% (922) 39.7% (123) 51.7% (1,045)
Region  
South 34.2% (586) 56.1% (174) 37.6% (760)
North 19.7% (337) 15.8% (49) 19.1% (386)
Central  22.7% (388) 20.3% (63) 22.3% (451)
West 23.4% (401) 7.8% (24) 21.0% (425)
Stage at Diagnosis  
Stage I 30.3% (518) 30.3% (94) 30.3% (612)
Stage II 38.4% (657) 32.3% (100) 37.4% (757)
Stage III 31.4% (537) 37.4% (116) 32.3% (653)
NCI Combined Comorbidity  
Score 
0.28 (0.43) 0.25 (0.40) 0.27 (0.43)
1Descriptive analysis is limited to surveillance colonoscopies occurring within 7 to 18 months after 
surgery. The sample size is larger in the Cox regression models because colonoscopies occurring 
outside of this time window are included as failures. 
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Table 11. 
 
Cox Proportional Hazard Model Regression Results. 
 
 
 Surgery to 
Chemotherapy1 
Surgery to 
Colonoscopy2 
Surgery to  
Death3 
 HR 95%CI p HR 95%CI p HR 95%CI p 
    
Demographic Characteristics       
Caucasian 0.82 0.38-1.76 0.61* 0.63 0.43-0.94 0.02* 0.94 0.79-1.12 0.49* 
Married 0.70 0.35-1.39 0.30* 1.28 0.91-1.78 0.15* 0.97 0.86-1.10 0.66* 
Age at Diagnosis        
<55 yrs  2.78 0.71-10.94 0.14* 1.58 0.89-2.81 0.12* 0.76 0.56-0.99 0.04* 
55-64 yrs  2.36 0.66-8.36 0.18* 1.28 0.82-1.99 0.27* 0.99 0.84-1.18 0.96* 
65-74 yrs  1.76 0.46-6.70 0.41* 1.60 1.03-2.47 0.04* 0.90 0.77-1.06 0.21* 
75+ yrs (ref)        
Region         
North 0.06 0.01-0.49 0.01* 0.90 0.56-1.44 0.65* 1.10 0.92-1.33 0.29* 
Central  0.33 0.11-0.97 0.04* 1.84 1.23-2.76 0.00* 0.99 0.84-1.18 0.96* 
West 0.39 0.15-0.99 0.05* 1.13 0.68-1.87 0.64* 1.02 0.86-1.21 0.85* 
South (ref)        
NCI Combined Comorbidity Score      
 1.69 0.68-4.19    0.26   1.44  0.92-2.26   0.11 1.01 0.89-1.15    0.83* 
Stage at Diagnosis       
Stage I -- -- -- 1.17 0.81-1.69 0.41* 0.84 0.71-0.99 0.04* 
Stage II (ref)          
Stage III -- -- -- 0.85 0.55-1.32 0.48* 1.32 1.13-1.53 0.00* 
N 632   1,083   991   
1-This measure was time from definitive surgical resection to initiation of 5-FU-based chemotherapy 
(Stage II-III). 
2-This measure was time from surgery to receipt of surveillance colonoscopy within 7-18 months 
(Stage I-III). 
3-This measure was time from surgery to death (Stage I-III). 
* Indicates statistical significance at the <0.05 alpha level. 
--Indicates that stage was not included in the surgery to chemotherapy timeliness measure because 
analysis was limited to patients with Stage II and III disease. 
  
 
CHAPTER 6: THE ASSOCIATION OF RACE WITH TIMELINESS OF CARE AND 
SURVIVAL AMONG VETERANS AFFAIRS HEALTHCARE SYSTEM PATIENTS 
WITH LATE-STAGE NON-SMALL CELL LUNG CANCER 
 
OVERVIEW 
NSCLC is the leading cause of cancer-related mortality in the United States. 
Patients with late-stage disease (Stage III/IV) have five-year survival rates of 2–15%. 
Care quality may be measured as time to receiving recommended care and, 
ultimately, survival. This study examined the association between race and receipt of 
timely NSCLC care and survival among Veterans Affairs (VA) healthcare system 
patients. 
Data were from a nationwide VA quality-monitoring program. We included 
Caucasian or African American (AA) patients diagnosed with pathologically 
confirmed late-stage NSCLC in 2006 and 2007. We examined three quality 
measures—time from diagnosis to: 1) treatment initiation, 2) palliative care or 
hospice referral, and 3) death. Unadjusted analyses used Log-rank and Wilcoxon 
tests. Adjusted analyses used Cox proportional hazard models. 
After controlling for patient and disease characteristics using Cox regression, 
there were no racial differences in time to initiation of treatment (72 for AA versus 65 
days for Caucasian patients, HR 1.03, p=0.80) or palliative care or hospice referral 
(129 versus 116 days, HR 1.10, p=0.34). However, our adjusted model found longer 
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survival for African American patients than for Caucasian patients (133 versus 117 
days, HR 1.31, p=0.00).  
For process measures of care quality such as time to initiation of treatment 
and referral to supportive care, the VA provides racially equitable care. The small 
racial difference in survival time of approximately two weeks is not clinically 
meaningful. Future work should validate this possible trend prospectively, with 
longer periods of follow-up, in other veteran groups. 
INTRODUCTION 
Lung cancer is the leading cause of cancer-related death, accounting for 29% 
of all cancer-related deaths among men (Siegel et al., 2012). NSCLC is responsible 
for approximately 85% of lung cancers (American Cancer Society, 2013). NSCLC 
has a dismal prognosis with five-year survival rates ranging from 49% for patients 
with Stage IA of the disease to approximately 1% for those with Stage IV (American 
Cancer Society, 2013). Because survival rates are poor, the goal of much therapy 
for late-stage NSCLC patients is palliative, often focusing on formal referrals to 
palliative care and/or hospice services. For patients with the late-stage disease 
recommended treatment ranges from chemotherapy and radiation with or without 
surgery (Stage IIIA), to chemotherapy and radiation without surgery or 
chemotherapy alone (Stage IIIB), to chemotherapy alone for patients with metastatic 
disease (Stage IV) (Cooper et al., 2002; Pfister et al., 2004). 
There is a clear link between quality of care and patient outcomes. Receipt of 
timely, stage-appropriate care for NSCLC patients can increase the length of 
survival (Hardy et al., 2009). Despite the IOM prioritizing the receipt of timely 
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treatment as a measure of quality (Institute of Medicine, 2001), many studies have 
identified differences in care quality among NSCLC patients of diverse races that 
may contribute to racial differences in outcomes (Olsson et al., 2009). In fact, there 
is evidence of racial disparities in care quality measures throughout the NSCLC 
treatment trajectory. Proper staging is essential for effective treatment planning, yet 
there are racial differences in receipt of positron emission tomography (PET) 
imaging to accurately stage patients (Gould et al., 2011). Once a patient has been 
staged, for those with early stage NSCLC, timely receipt of surgical resection has a 
critical impact on survival outcomes. Several studies have shown that African 
American patients are less likely to receive surgical resection than their Caucasian 
counterparts (Farjah et al., 2009; Margolis et al., 2003). Racial differences also exist 
in terms of patient treatment refusal rates (Landrum, Keating, Lamont, Bozeman, & 
McNeil, 2012) appropriateness and timeliness of care among Medicare 
beneficiaries, and survival (Shugarman et al., 2009). One study found that, relative 
to Caucasian patients, African American patients were 34% less likely to receive 
timely surgery, chemotherapy, or radiation for Stage III NSCLC and were 51% less 
likely to receive chemotherapy in a timely fashion for Stage IV disease (Shugarman 
et al., 2009).  
Although the existence of racial disparities in NSCLC is well documented, the 
etiology of these racial differences is complex. Reasons include a cumulative effect 
of both patient and health system factors. Evidence suggests that when patients 
receive the right care at the right time, there is little racial difference in survival rates. 
For example, among SEER patients, there was a 3% absolute difference in survival 
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favoring Caucasian patients over minorities (Morris, Rhoads, Stain, & Birkmeyer, 
2010). In an analysis of late-stage NSCLC Medicare beneficiaries, the five-year 
survival rates for Caucasian and African American patients were 17.7% and 19.6% 
respectively. After controlling for socioeconomic status, this difference entirely 
dissipated (Hardy et al., 2009). Similarly, after controlling for receipt of surgery, 
differences in survival rates for early-stage NSCLC patients were comparable across 
racial groups (Bach et al., 1999). Similar survival rates by race were found among 
veterans with early-stage disease who received surgery (Jahanzeb, Virgo, 
McKirgan, & Johnson, 1997; Williams, Provenzale, Stechuchak, & Kelley, 2012). 
The Veterans Affairs (VA), the largest integrated U.S. healthcare system, is 
reputed as an equal access provider (Kizer & Dudley, 2009). As such, the VA 
provides an excellent environment in which to study quality of cancer care among 
patients with NSCLC. We hypothesize that if patients received equitable and timely 
care, there will subsequently be similar survival rates by race. Focusing on patients 
with late-stage NSCLC (Stage III and IV), we expand previous work by examining 
racial differences in two dimensions of quality of VA NSCLC care: processes of care 
(time to treatment) and outcomes (survival).  
METHODS 
Data Source 
The Veterans Health Administration (VHA) Office of Analytics and Business 
Intelligence (formerly the Office of Quality and Performance) conducted the EPRP 
Lung Cancer Special Study to evaluate the quality of lung cancer care provided in 
the VA. As previously described (Williams, Stechuchak, Zullig, Provenzale, & Kelley, 
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2012), patients were identified through the VA Central Cancer Registry (Zullig et al., 
2012). Patients were eligible for the EPRP study if they were: diagnosed with lung 
cancer between October 1, 2006, and December 31, 2007; documented pathologic 
confirmation of lung cancer in the electronic medical record; and survived at least 
thirty-one days post-diagnosis. Patients were excluded for any of the following 
reasons: lung cancer diagnosed during autopsy; enrollment in hospice less than 
thirty-one days post-diagnosis; enrollment into a cancer clinical trial; pre-existing or 
concurrent diagnosis of metastatic cancer (other than lung cancer), documentation 
of comfort measures only, or life expectancy of six months or less. Data were 
manually abstracted from a national electronic medical record by trained abstractors 
between February 3, 2010, and August 11, 2010. 
Measures 
The analytic data set consisted of African American and Caucasian patients 
with pathologically confirmed late-stage (Stage III or Stage IV) NSCLC. We 
assessed three dependent variables. We included two process measures of care 
timeliness: 1) time from diagnosis to initiation of treatment (surgery, chemotherapy, 
radiation therapy, or admission into palliative care or hospice); and 2) time from 
diagnosis to referral to palliative care or hospice. The third measure was time from 
diagnosis to death. Death information was obtained during data abstraction, 
approximately two years from diagnosis. For all measures, time was expressed as 
the number of days between events.  
The primary independent variable of interest was patients’ race. Because 
there were relatively few non–African American minority patients in the cohort 
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(n=56), we restricted our analyses to African American and Caucasian patients; we 
lacked data on Hispanic ethnicity. Covariates included demographic characteristics 
(age at diagnosis, marital status, and geographic region) and clinical factors (stage 
at diagnosis and performance status) previously associated with timeliness of care 
(Pagano et al., 2010; Zheng et al., 2012). Patients were considered to have poor 
performance status if the medical record contained documentation of any of the 
following: Eastern Cooperative Oncology Group (ECOG) score greater than two, 
Karnofsky Performance Status Scale of less than 60%, and/or an Adult Evaluation 
Comorbidity-27 (ACE-27) score of moderate or severe (2 or 3). Non–African 
American minority patients, those missing race information, and duplicate records 
were excluded from the final analytic data set.  
Statistical Analysis 
The Kaplan-Meier method was used to estimate time-to-event curves. The 
models did not converge when attempting to control for geographic clustering. We 
present the racial distribution of key variables (stage at diagnosis, performance 
stage, age). To compare differences in unadjusted survival curves between African 
American and Caucasian patients, we used the Log-rank and Wilcoxon tests. 
Multivariate Cox proportional hazard models were used to examine the association 
between race and time-to-event after controlling for the previously mentioned 
covariates. The Efron method was used to handle ties (Cleves et al., 2010; 
Kleinbaum, 1996). Statistical significance was assessed at a conventional alpha 
level of <0.05. Data management and analyses were conducted in Stata 11 
(StataCorp LP, College Station, TX) and SAS version 9.2 (SAS Institute, Cary, NC). 
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RESULTS 
Our final analytic sample consisted of 2,200 patients with NSCLC (Figure 6). 
At the time of diagnosis, 83% were Caucasian; 46% were married; 33% were aged 
55–64 years; and 47% lived in the South (Table 1). The majority of patients (89%) 
were diagnosed with metastatic disease and 65% had documentation of poor 
performance status. Overall, the mean time from diagnosis to initiation of treatment 
(defined as first date of chemotherapy, radiation therapy, or admission to palliative 
care or hospice; patients may have had multiple treatment modalities) was sixty-six 
days, or approximately two months. When examining racial groups separately, the 
mean times to initiation of treatment were similar for Caucasian and African 
American patients (65 versus 71 days, respectively). The mean time between 
diagnosis and referral to palliative care or hospice was 188 days with Caucasian 
patients being referred an average of fourteen days earlier (115 days versus 129 
days). The mean time from diagnosis to death was approximately 120 days, or four 
months, with Caucasian patients dying sixteen days sooner than African American 
patients (117 versus 133 days) (Table 12). Patients were similar by race with regard 
to stage at diagnosis (p=0.48) and performance status (p=0.85).  
Approximately 70% of patients received treatment for their NSCLC. For 
patients who received treatment, the mean time to initiation of treatment was forty-
four days. In unadjusted analysis, there were no racial differences in time to initiation 
of treatment (Wilcoxon p=0.94; Log-rank p=0.99). After adjustment there remained 
no association between time to initiation of treatment and race (HR 1.03, p=0.80), 
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marital status (HR 1.00, p=0.98), age at diagnosis, region, stage at diagnosis (HR 
0.87, p=0.47), or performance status (HR 0.81, p=0.09) (Table 12).  
Over half (54%, n=1,178) of patients were referred to palliative care or 
hospice, with referral occurring approximately 118 days after diagnosis. In 
unadjusted analyses, there were no racial differences in time to palliative care or 
hospice referral (Wilcoxon p=0.29; Log-rank p=0.57). The lack of association by race 
remained in the adjusted Cox models (HR 1.10, p=0.34) (Table 13). Compared to 
patients with Stage IV disease, those with Stage III had approximately a 36% higher 
hazard of referral (HR 1.37, p=0.00) to palliative care or hospice. Compared to 
patients with documentation of poor performance status, healthier patients had 
approximately a 20% reduced hazard of referral (HR 0.81, p=0.01) to palliative care 
or hospice. There were no other associations between referral and patients’ socio-
demographic characteristics. 
At the time of data collection, approximately 78% of the sample was 
deceased, with a mean time from diagnosis to death of approximately 120 days or 
four months. In unadjusted analysis, Caucasians died sooner than African 
Americans (Wilcoxon p=0.00; Log-rank p<0.01). This finding remained after 
adjusting for covariates (HR 1.31, p<0.01). Being married (HR 0.89, p=0.02) and 
under 55 years of age (HR 0.76, p=0.01) were protective against death compared to 
being unmarried and/or over 75 years old at diagnosis. Geographic region was not 
associated with time to death. Compared to those with metastatic disease, patients 
with Stage III disease had approximately a 50% reduced hazard of death (HR 0.53, 
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p<0.01). Poor performance status was also associated with time to death (HR 0.80, 
p<0.01) (Table 12). 
DISCUSSION 
We examined two dimensions of quality of VA NSCLC care: processes of 
care (time to treatment) and outcomes (survival). Among patients with late-stage 
NSCLC, we observed no racial differences in processes of care. In fact, there were 
no significant associations between time from diagnosis to initiation of treatment and 
any patient-level characteristics. This supports the VA’s reputation as an equal 
access system. The mean time to first treatment that we observed, approximately 
sixty-six days, is consistent with a previous VA study of advanced NSCLC (Schultz 
et al., 2009). While some have argued that a two-month delay may negatively effect 
patients’ emotional state (Gould, 2009) there are no formalized guidelines regarding 
timeliness of treatment for NSCLC. Thus, these findings suggest that the VA 
provides equitable and timely access to critical health services for patients with late-
stage NSCLC.  
Palliative care is critical for effective management of pain and other 
distressing symptoms and is often provided in conjunction with other therapies. 
Recent literature has suggested that enrollment in hospice does not compromise the 
length of survival for patients following advanced lung cancer diagnosis (Saito et al., 
2011) and may in fact extend life by two months (Temel et al., 2010). As a result, 
some have suggested that patients be referred to palliative care within four to six 
weeks of diagnosis (von Gunten, Lutz, & Ferris, 2011). In the absence of timeliness 
standards, it is clear that the VA is committed to referring all patients in a common 
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timeframe. We found that over half of patients with advanced NSCLC were referred 
to palliative care or hospice services, with no significant racial differences. Moreover, 
these data suggest that patients seem to be appropriately referred based on their 
health status as patients with metastatic disease and/or poor performance status 
were sent to palliative care and/or hospice more quickly. 
We also examined survival rates up to two years from diagnosis. As 
anticipated, we found that metastatic disease, poor performance status, and 
increased age at diagnosis were associated with shorter survival times. Marriage 
had a protective effect, which has also been demonstrated in prior studies (Siddiqui 
et al., 2010). In these data, African American patients survived at mean of sixteen 
days longer compared to Caucasian patients, even after controlling for pre-specified 
covariates. Though racial differences in survival time have been documented in non-
federal healthcare systems, our finding is consistent with several studies suggesting 
that once equal access to care has been obtained, survival rates are similar for 
patients of diverse races (Akerley et al., 1993; Bradley et al., 2001; Zheng et al., 
2012). 
Our study has several limitations. First, our analysis was limited to care 
received in the VA. Some patients receiving care in the VA healthcare system may 
also receive a portion of their cancer care in the private sector. Analysis was also 
limited to patients of African American and Caucasian race without regard to 
Hispanic ethnicity. Geographic regions were defined based on land mass, not 
distribution of this sample or VA patients. Future research should endeavor to 
include information from multiple data sources on a more diverse patient cohort. We 
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obtained death information two years post-diagnosis, however, this seems 
reasonable as 78% of our sample died within this timeframe. 
Our findings provided important insights on the quality and timeliness of VA 
NSCLC care. We assessed key process and outcome measures of care quality and 
observed no evidence of clinically meaningful racial differences in timeliness of 
NSCLC care provided by the VA healthcare system. To validate these findings, 
future studies that follow patients longitudinally should be conducted. These results 
may reflect the VA’s history as an equal access system (Kizer & Dudley, 2009; 
Perlin et al., 2004; Robinson et al., 2010) and its established commitment to ongoing 
quality monitoring and improvement. 
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Figure 6. Lung cancer cohort assembly. 
EPRP Lung Cancer Special 
Study database of patients 
diagnosed with lung cancer in 
2007 
n=7,817 
VA Central Cancer Registry 
(VACCR) database of 
demographic information for 
patients diagnosed with lung 
cancer in 2007 
n=8,267 
Combined EPRP-VACCR 
database 
n=7,809 
Patients with non-small cell 
lung cancer (NSCLC) 
n=6,307 
Exclude patients without 
NSCLC 
n=1,502 
Patients pathologic 
confirmation of NSCLC 
n=5,836 
Exclude patients without 
pathologic confirmation of 
NSCLC 
n=471 
Patients with Stage III or IV 
NSCLC 
n=2,259 
Exclude patients missing 
stage, Stage I, or Stage II 
n=3,577 
Patients of Caucasian or 
African American race 
n=2,203 
Exclude patients of other 
minority race or missing race 
information 
n=56 
Final analytic sample 
n=2,200 
(note that specific n’s vary by 
measure) 
Exclude duplicate patients 
n=3 
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TABLE 12. 
 
Description of NSCLC Patient Cohort and Key Variables. 
  Caucasian 
Patients 
(n=1,826) 
AA  
Patients 
(n=374) 
Full  
Sample 
(n=2,200) 
 % (n) or Mean 
(SD) 
% (n) or 
Mean (SD) 
% (n) or 
Mean (SD) 
Dependent variables   
Days from diagnosis to initiation 
of treatment1 
64.9 (84.2) 71.5 (89.8) 66.0 (85.2)
Days from diagnosis to referral 
to palliative care or hospice 
115.5 (102.5) 129.4 (108.1) 117.8 (103.6)
Days from diagnosis to death 116.8 (92.0) 132.9 (100.5) 119.5 (93.7)
Independent variable  
Caucasian race 100.0% (1,826) 0.0% (374) 83.0% (1,826)
Other control variables  
Age at Diagnosis  
<55 years  7.0% (127) 12.3% (46) 7.9% (173)
55-64 years   32.7% (597) 36.9% (138) 33.4% (735)
65-74 years   26.0% (475) 23.8% (89) 25.6% (564)
75+ years 27.2% (496) 21.4% (80) 26.2% (576)
Married 47.5% (866) 35.4% (132) 45.5% (998)
Region  
South 43.8% (799) 62.0% (232) 46.9% (1,031)
North 13.3% (243) 10.2% (38) 12.8% (281)
Central  23.4% (428) 16.0% (60) 22.2% (488)
West 19.5% (356) 11.8% (44) 18.2% (400)
Stage at Diagnosis  
Stage III 11.3% (206) 12.6% (47) 11.5% (253)
Stage IV 88.7% (1,620) 87.4% (327) 88.5% (1,947)
Poor Performance Status2 65.0% (1,186) 64.4% (241) 64.9% (1,427)
1-Treatment included initiation of lung cancer surgery, chemotherapy, radiation 
therapy, admission into palliative care, or admission into hospice. 
2-Patients were considered to have poor performance if the medical record 
contained documentation of an ECOG score >2, a Karnofsky of <60%, or an ACE-
27 score of 2 (moderate) or 3 (severe). 
 Table 13. 
 
Cox Proportional Hazard Model Regression Results. 
 Diagnosis to Treatment 
Initiation1 
Diagnosis to Referral to 
Palliative Care or Hospice Diagnosis to Death 
 HR 95%CI p HR 95%CI p HR 95%CI p 
    
Demographic Characteristics          
 Caucasian race 1.04  0.78-1.37 0.80 1.10  0.91-1.34 0.34* 0.31  1.14-1.50 0.00* 
 Married 1.00  0.81-1.25 0.98 1.02  0.88-1.12 0.78* 0.89  0.81-0.99 0.02* 
Age at Diagnosis          
 <55 years  0.82  0.56-1.22 0.34 0.83  0.63-1.10 0.19* 0.76  0.62-0.92 0.01* 
 55-64 years  0.97  0.75-1.27 0.83 0.90  0.75-1.09 0.27* 0.89  0.80-1.00 0.06* 
 65-74 years  1.04  0.79-1.37 0.79 0.99  0.82-1.20 0.92* 0.88  0.78-1.00 0.06* 
 75+ years (ref)          
Region          
 North 1.02  0.71-1.46 0.92 0.87  0.67-1.13 0.29* 1.10  0.95-1.28 0.19* 
 Central  0.89  0.67-1.18 0.40 0.89  0.73-1.08 0.24* 1.13  1.00-1.27 0.06* 
 West  0.87  0.64-1.17 0.36 0.96  0.78-1.18 0.69* 1.08  0.95-1.24 0.23* 
 South (ref)          
Poor Performance Status 0.81  0.64-1.03 0.09 0.81  0.69-0.95 0.01* 0.80  0.72-0.89 0.00* 
Stage at Diagnosis          
 Stage III 0.87  0.59-1.28 0.47 1.37  1.13-1.64 0.00* 0.53  0.45-0.63 0.00* 
 Stage IV (ref)          
N 2,098   2,149   2,190   
1-First treatment could have been chemotherapy, radiation therapy, or admission to palliative care or hospice. 
* Indicates statistical significance at the <0.05 alpha level. 
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 CHAPTER 7: SUMMARY OF FINDINGS AND IMPLICATIONS FOR POLICY, 
PRACTICE, AND RESEARCH 
 
Summary of Findings 
This dissertation examined racial differences in quality and timeliness of VA 
cancer care. We assessed these issues among patients with CRC and advanced 
NSCLC, two common and often deadly diseases. In Chapter 4, we examined the 
association between race and receipt of NCCN guideline–concordant CRC care. In 
non-federal U.S. healthcare systems, racial differences throughout the continuum of 
CRC care have been extensively documented (Benarroch-Gampel et al., 2012; 
Berry et al., 2009; Berry et al., 2010; Crawford et al., 2010; Dimou et al., 2009; Du et 
al., 2011; Kim et al., 2011; Obeidat et al., 2010; Rhoads et al., 2012; Singh et al., 
2011; White et al., 2010). As an integrated healthcare system and an accountable-
care organization, the VA provides a unique platform from which to study potential 
racial differences in cancer care quality.  
We used observational, retrospectively abstracted data on a national cohort 
of veterans diagnosed with incident CRC to assess the association between race 
and several stage-specific quality measures. For patients with Stage II or III disease 
these measures included receipt of computed tomography scan, preoperative 
carcinoembryonic antigen, clear surgical margins, and referral to medical oncology. 
For patients with Stage III disease we examined receipt of fluorouracil-based 
adjuvant chemotherapy, and for patients with Stages I–III disease, we examined 
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receipt of guideline-appropriate surveillance colonoscopy. 
Across all NCCN measures, we identified few significant associations 
between patient characteristics and quality care. For example, older age at 
diagnosis was associated with reduced odds of medical oncology referral and 
surveillance colonoscopy. Presence of cardiovascular comorbid conditions was 
marginally associated with reduced odds of medical oncology referral (OR 0.65, 95% 
CI 0.50-0.89). Odds of receiving surveillance colonoscopy were lower among 
patients with Stage I disease (OR 0.71, 95% CI 0.56-0.90) compared to Stage II. 
The key finding presented in Chapter 4 was that there were no significant racial 
differences in receipt of guideline-concordant CRC care. This lack of disparity is in 
contrast to care received in much of the private sector, suggesting that the VA may 
be a leader in providing racially equitable care.  
In Chapter 5 we further studied potential racial differences in care by delving 
beyond simple receipt of care, as measured in Chapter 4, and incorporated a time 
element. Chapter 5 examined two unique aspects of VA CRC quality care: 
processes (time to treatment) and outcomes (survival). We examined three quality 
indicators—time from: 1) surgery to initiation of adjuvant chemotherapy (Stage II-III); 
2) surgery to surveillance colonoscopy (Stage I-III); and 3) surgery to death (Stage I-
III). 
In unadjusted analyses across all three timeliness measures, there was no 
evidence of racial differences. In adjusted Cox proportional hazard regression 
models, there were no racial differences in time to initiation of chemotherapy (HR 
0.82, p=0.61) or surgery to death (HR 0.94, p=0.49). However, we found that 
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Caucasian patients experienced slightly shorter median times to surveillance 
colonoscopy than African American patients (367 versus 383 days, HR 0.63, 
p=0.02). This equates with an average difference of approximately sixteen days, or 
slightly over two weeks, in time to surveillance colonoscopy between racial groups. 
This difference is small and there is no scientific evidence to suggest that a two-
week delay would have a negative impact on patient outcome. However, this 
potential difference is worth validation and further monitoring in prospective studies 
of veteran populations. 
As an outcome of care quality, we examined post–CRC surgical resection 
survival times and identified similar times among patients of Caucasian and African 
American race. This critical finding may signal that the VA provides similar 
processes of quality care to patients throughout their disease trajectory. 
Subsequently, this comparable care may translate into equivalent survival times.  
Paralleling Chapter 5, in Chapter 6 we examined process (time to treatment) 
and outcomes (survival) measures among VA patients with advanced NSCLC. 
NSCLC is responsible for nearly 19% of all cancers diagnosed and treated in the VA 
healthcare system (Zullig et al., 2012) and is the leading cause of cancer-related 
death (Siegel et al., 2012), making it an important disease in which to understand 
potential racial differences in care quality. As in the previous chapters, we used 
observational, retrospectively data abstracted from the VA’s national electronic 
health record. We examined three quality measures—time from diagnosis to: 1) 
treatment initiation; 2) palliative care or hospice referral; and 3) death among VA 
patients with advanced NSCLC.  
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In adjusted Cox proportional hazard regression models there were no racial 
differences in time to initiation of treatment (HR 1.03, p=0.80; difference of seven 
days on average between racial groups) or palliative care or hospice referral (HR 
1.10, p=0.34; difference of thirteen days on average between racial groups). 
However, the adjusted Cox proportional hazard regression model revealed slightly 
longer survival for African American patients (133 days) compared to Caucasian 
patients (117 days; HR 1.31, p=0.00). The difference was a mere sixteen days, or 
slightly more than two weeks. This small racial difference in survival time is not 
clinically meaningful and may be the result of unmeasured differences between 
patient groups at the time of diagnosis.  
Echoing findings from the CRC patient cohort (Chapter 5), for process 
measures of care quality such as time to initiation of treatment and referral to 
supportive care, the VA provides racially equitable NSCLC care. We identified a 
slight dissimilarity in survival times among NSCLC patients of diverse races; 
however this difference is unlikely to have clinical meaning. Our analysis focused on 
two-year survival rates. Though few patients were living two years post-diagnosis, 
future studies could build on these findings by considering a longer-range survival 
time and by confirming this possible trend prospectively in other veteran groups. 
Implications for Policy, Practice, and Research 
The key finding of this dissertation was that the VA provides quality cancer 
care to patients regardless of race. This result has considerable implications for 
health services policy, clinical practice, and future research. The VA serves a racially 
diverse population within the structure of an ACO. Many private U.S. healthcare 
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systems are restructuring to become more comparable to the VA’s ACO model. 
There may be opportunity for the VA and the private sector to learn from each 
other’s successes in delivering quality, equitable care. Specifically, there may be 
quality improvement initiatives, electronic reminder systems, or other projects 
developed within the VA healthcare system that may be readily translatable for use 
in other hospitals or healthcare systems.  
The causal pathways to the VA’s racial equity or care quality were not 
assessed in our analyses. However, our findings may suggest that the VA’s efforts 
for continuous quality improvement and universal accessibility are successful in 
assuring delivery of high-quality cancer care. The VA has a centralized plan for 
ongoing quality monitoring and improvement. This focus on quality improvement 
includes many strategies such as the EPRP and national collaboratives targeting 
improved delivery of cancer care. Future research studies should examine which 
strategies are most effective in ensuring quality care. 
Largely due to improved methods for early detection and treatment of many 
cancers, the number of cancer survivors treated within the VA system is increasing. 
In fiscal year 2007, approximately 11% of VA patients were cancer survivors (Moye, 
Schuster, Latini, & Naik, 2010). This increasing population of cancer survivors may 
instigate a shift in demand for health services—critical information given the potential 
shortage of both primary care physicians and medical oncologists. Future studies 
should examine ways to integrate existing quality improvement strategies into 
assuring quality care for cancer survivors, reconnecting them with primary care 
services while still obtaining recommended cancer surveillance.  
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Conclusion 
Racial disparities in healthcare are a serious problem. Over a decade ago, 
the Institute of Medicine asserted that there is no singular etiology underlying health 
and mortality disparities. There are a host of patient-, provider-, and system-
generated reasons for these disparities, but chief among the potential causal factors 
was lower quality of care delivered to patients of racial minority groups (Nelson, 
2003). There have been many initiatives, both at the local and national level, to 
document and reduce disparities in all aspects of healthcare.  
The findings of this dissertation suggest that VA cancer care may be an 
exemplar of an equal-access healthcare delivery system. Across myriad metrics, the 
VA provided racially equitable cancer care. The VA healthcare system provides 
evidence that a large, integrated healthcare system can serve a diverse patient 
population and deliver quality cancer care to all of its patients. 
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